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21 Recently, it has become evident that pharmaceutical excipients may interfere with the activity of ATP-
22 binding cassette (ABC) transporters and solute carriers (SLC). The present review aims to provide an 
23 overview of surfactants shown to modulate substrate transport via SLCs and ABCs, and to discuss the 
24 relevance for oral drug absorption. In vitro, more than hundred surfactants have been suggested to 
25 decrease the efflux activity of P-glycoprotein (P-gp, ABCB1), and many of these surfactants also 
26 inhibit the breast cancer resistance protein (BCPR, ABCG2), while conflicting results have been 
27 reported for multidrug resistance-associated protein 2 (MRP2, ABCC2). In animals, surfactants such as 
28 pluronic® P85 and polysorbate 20 have been shown to enhance the oral absorption of P-gp and BCRP 
29 substrates. Many surfactants, including cremophor® EL and Solutol® HS 15 inhibiting ABC 
30 transporters, were also found to inhibit SLCs in cell cultures. These carriers were SLC16A1, SLC21A3, 
31 SLC21A9, SLC15A1-2, and SLC22A1-3. This overlap in specificity of surfactants that inhibit both 
32 transporters and carriers might influence the oral absorption of various drug substances, nutrients, and 
33 vitamins. Such biopharmaceutical elements may be relevant for future drug formulation design.
34
35 Key words: Nonionic surfactant, Co-surfactant, ATP-binding cassette transporters, Solute carriers, 







41 Today, many drug substances approved for oral and parenteral use are prepared in surfactant containing 
42 formulations such as lipid-based formulations, suspensions and solid dosage forms (Savla et al., 2017). 
43 In these formulations, nonionic surfactants are used as solubilizes, stabilizers, wetting agents etc. In the 
44 lastrecent years, it has become evident that some surfactants may affect the function of biological 
45 membrane transport proteins by altering drug substance uptake (Engel et al., 2012; Rege et al., 2002) 
46 and/or cellular efflux (Batrakova et al., 2003a; Rege et al., 2002; Yamagata et al., 2007b). Membrane 
47 transport proteins relevant to drug transport are from two major families, i.e. the ATP-binding cassette 
48 (ABC) family of efflux transporters and the solute carrier (SLC) family of cellular influx and efflux 
49 carriers. In brief, members of the ABC family (hereafter termed “transporter”) depend directly on the 
50 use of cellular ATP to complete their transport cycle, which in mammals result in cellular efflux. 
51 Members of the SLC family do not directly depend on using cellular ATP, but are driven by substrate 
52 concentrations and in many cases the concentration gradient of other substrates such as ions. A SLC 
53 facilitates either cellular influx or efflux, and are hereafter termed “carrier”. Currently, the ABC and 
54 SLC families consist of 51 and 417 members (HUGO Gene Nomenclature Committee, 2019), 
55 respectively. The first indication that pharmaceutical excipients could alter the transport function of 
56 transporters and carriers came from observations that nonionic surfactants such as cremophor® EL 
57 (Woodcock et al., 1990), Solutol® HS 15 (Coon et al., 1991), and polysorbate 80 (Woodcock et al., 
58 1992) reversed multidrug resistance in cancer cells. In cell cultures, nonionic surfactants inhibited 
59 different members of the ABC family such as P-glycoprotein (P-gp, MDR1, ABCB1) (Lo, 2003; Rege 
60 et al., 2002), breast cancer resistance protein (BCRP, ABCG2) (Yamagata et al., 2007a, b), and 
61 multidrug resistance-associated protein 2 (MRP2, ABCC2), although conflicting results have been 
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62 observed for MRP2 (Hanke et al., 2010; Li et al., 2013a, 2014). In vivo, in wild type animals, nonionic 
63 surfactants have been shown to enhance the intestinal absorption and bioavailability of P-gp substrates 
64 such as digoxin (Cornaire et al., 2004; Nielsen et al., 2016; Zhang et al., 2003), etoposide (Akhtar et al., 
65 2017; Al-Ali et al., 2018a), and paclitaxel (Varma and Panchagnula, 2005), and the BCRP substrate 
66 topotecan (Yamagata et al., 2007b). Interestingly, corresponding control experiments in transporter 
67 deficient animals showed that co-administration of nonionic surfactants with digoxin (Nielsen et al., 
68 2016) or etoposide (Al-Ali et al., 2018a) in mdr1a deficient rats, or topotecan (Yamagata et al., 2007b) 
69 in abcg2 deficient mice did not alter the oral absorption and bioavailability of these substrates. This 
70 indeed indicates that surfactants increase intestinal absorption through P-gp or BCRP inhibition, and 
71 for the drug substances in question, not through unspecific effects related to solubilizing of the drug 
72 substances or through permeation enhancing effects.
73 Recently, in vitro studies have also shown that nonionic surfactants such as polysorbate 20 and 
74 cremophor® EL inhibit the transport via several SLCs expressed ion the apical membrane of 
75 enterocytes such as the organic anion transporting polypeptide 1A2 (OATP1A2, SLC21A3) (Engel et 
76 al., 2012) and organic cation transporters (OCT1-3, SLC22A1-3) (Otter et al., 2017; Soodvilai et al., 
77 2017). These observations indicate that biopharmaceutical considerations need to be an important part 
78 of new formulation development when formulations contain pharmaceutical excipients such as 
79 surfactants and co-surfactants because these excipients may have different impacts on transporters and 
80 carriers. Therefore, addition of surfactants to obtain an enabling formulation may potentially influence 
81 the oral absorption (positively or negatively) of a co-administered drug substance if this is a substrate 
82 for a carrier and/or transporter. On the other hand, enabling formulations provide the formulation 
83 scientist with the possibility to adjust drug absorption to become more consistent by selecting 
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84 appropriate excipients for drug substances that are ABC and/or SLC substrates. To do so, it becomes 
85 important to understand: 1) the different impacts of nonionic surfactants on carriers and/or transporters, 
86 2) the mechanism behind surfactant-protein interactions, and 3) whether such impacts of surfactants on 
87 substrate-protein interactions observed in cell cultures may affect the pharmacokinetics parameters of 
88 the substrates in vivo. Currently, the translational aspects of how excipients affect carriers and 
89 transporters in vivo and how this may be exploited for formulation design are largely unexplored. 
90 This review aims to provide an overview of surfactants shown to modulate substrate transport via 
91 transporters and carriers, and to discuss the relevance for oral drug absorption, and when possible the 
92 mechanism behind the interaction. In this paper, essential data is presented in tables, whereas more 
93 comprehensive overviews are provided in a supplementary tables in order to enhance the readability of 
94 the review. 
95
96 2. Modulation of intestinal transporters and carriers
97 In the 1980s, modulation of membrane transport proteins was originally proposed as a strategy for 
98 chemo-sensitizing cancer cells and to increase the oral bioavailability of drug substances that were 
99 substrates for the efflux transporter P-gp in humans. Therefore, inhibitors of efflux transporters such as 
100 P-gp and BCRP were then identified and these inhibitors, for example verapamil (Tsuruo et al., 1981), 
101 dexverapamil (Gramatté and Oertel, 1999), valspodar (vanAsperen et al., 1997), and GF120918 (Hyafil 
102 et al., 1993), showed promising results in inhibiting P-gp (GF120918 also inhibited BCRP) 
103 (Maliepaard et al., 2001a), in pre-clinical studies. However, this strategy failed to produce safe and 
104 effective treatment in human clinical trials (Dalton et al., 1995; Greenberg et al., 2004; Lehnert et al., 
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105 1998; Mross et al., 1999; Planting et al., 2005; Ries and Dicato, 1991; Sparreboom et al., 1999; Warner 
106 et al., 1998). Subsequently, other strategies based on natural products (Appendino et al., 2003; Yoshida 
107 et al., 2005) and pharmaceutical excipients (Lo, 2003; Rege et al., 2002; Regev et al., 1999; Zhang et 
108 al., 2003) were suggested. In the latter group of compounds, nonionic surfactants gained quite some 
109 attention since many surfactants were found to enhance the intracellular accumulation of anticancer 
110 drugs including daunorubicin, vinblastine, and etoposide in cancer cells (Buckingham et al., 1995; 
111 Woodcock et al., 1990), and to influence the translocation activity of several transporters (Batrakova et 
112 al., 2001; Lo, 2003; Rege et al., 2002) and carriers (Rege et al., 2002). In terms of intestinal absorption, 
113 it has been reported that nonionic surfactants such as cremophor® EL (Rege et al., 2002), polysorbate 
114 80 (Lo, 2003), and d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS 1000) (Bogman et al., 
115 2005) increased the absorptive permeability and decreased the secretory permeability of the P-gp 
116 substrates drug substances rhodamine 123, epirubicin, and talinolol, respectively, in vitro using the 
117 Caco-2 cell monolayers model. Likewise, in intestinal segments of rats, surfactants such as TPGS 1000 
118 (Varma and Panchagnula, 2005) and polysorbate 40 (Zhu et al., 2009) enhanced mucosal to serosal (M-
119 S) permeability and decreased S-M permeability of P-gp substrates paclitaxel and rhodamine 123, 
120 respectively. Moreover, in vivo, it has been shown that Solutol® HS 15 (Bittner et al., 2002), 
121 polysorbate 80 (Zhang et al., 2003), and pluronic® P85 (Föger et al., 2006) enhanced the oral 
122 absorption and exposure of P-gp substrates colchicine, digoxin, and rhodamine 123, respectively. 
123 Consequently, it was evident that nonionic surfactants could be potential alternatives to conventional P-
124 gp inhibitors.  
125 Since the majority of research performed until now, has been focused on investigating the influence of 
126 nonionic surfactants on P-gp, BCRP, and MRP2 transporters, and on carriers including monocarboxylic 
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127 acid transporter (MCT), OATP1A2, OATP2B1, OCT1-3 and peptide transporters 1 and 2 (PEPT1 and 
128 2), this review will therefore summarize and discuss the impact of nonionic surfactants on these 
129 transporters and carriers in vitro and on the intestinal absorption of substrate drug substances in vivo.
130
131 3. Expression of selected transporters and carriers along the human intestine 
132 The intestinal expression of transporters and carriers have been studied for years using various mRNA-
133 based techniques, such as northern blotting and RT-PCR, as well as protein quantification methods, e.g. 
134 western blotting. As an example, Broberg et al. studied the expression of the proton-coupled amino 
135 acid transporter PAT1 along the length of the rat intestine taking samples from each 5 cm and 
136 measured the pat1 mRNA expression in each segment (Broberg et al., 2012). Recently, the emerging of 
137 high-resolution MS/MS-based techniques, membrane proteomics has received attention as a tool to 
138 describe the absolute transporter or carrier abundance in enterocytes. Knowing transporter and carrier 
139 abundancies in the intestine is important for understanding the absorption windows of drug substances 
140 (Oswald et al., 2006) and drug-drug interactions (Giacomini et al., 2010). Furthermore, absolute 
141 transporter and carrier abundance in different segments of the intestine is necessary for PBPK 
142 modelling (Harwood et al., 2013). The present section will briefly review the transporter and carrier 
143 abundance in the human intestine and Caco-2 cells of the selected transporter and carriers discussed in 
144 the present review. 
145 Table 1 shows protein concentrations of selected transporters and carriers in Caco-2 cells and in 
146 different regions of the human intestine. Naturally, cell differentiation affects transport and carrier 
147 protein expression, which is was also shown by Uchida et al. (Uchida et al., 2015). Therefore, we only 
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148 compare expression levels in cells with a similar degree of differentiation, and all three studies have 
149 shown investigated the expression in Caco-2 cells cultured for three weeks. Expression levels in cells 
150 obtained from different cell banks may vary to a high degree as illustrated for the glucose carrier 
151 SGLT1 by Steffansen and co-workers (Steffansen et al., 2017). For this reason, we have compared 
152 studies of Caco-2 cells from different cell banks (DSMZ, ECACC, and ATCC). The most extensive 
153 and systematic work in regional transporter and carrier expression in the intestine has been performed 
154 by Drozdzik and co-workers (Drozdzik et al., 2019; Drozdzik et al., 2014)
155 Regarding transporters, the P-gp expression rangeds from low to high (Akazawa et al., 2018; Drozdzik 
156 et al., 2019; Drozdzik et al., 2014; Gröer et al., 2013; Harwood et al., 2015; Lloret-Linares et al., 2016), 
157 and the expression increaseds from the proximal small intestine towards the distal small intestine 
158 (Akazawa et al., 2018; Drozdzik et al., 2014; Gröer et al., 2013) and drops decreased in the colon to 
159 levels similar to those in the proximal small intestine (Table 1) (Drozdzik et al., 2019; Drozdzik et al., 
160 2014). Caco-2 cells expressed slightly elevated levels of P-gp, compared to the small intestine (Brück 
161 et al., 2017; Uchida et al., 2015; Ölander et al., 2016). BCRP expression varieds between the studies 
162 from low (Drozdzik et al., 2014) to very high (Akazawa et al., 2018) expression in the small intestine 
163 with an increasing expression from the proximal to the distal part of small intestine (Drozdzik et al., 
164 2019; Drozdzik et al., 2014). In the colon, very low to intermediate expression of BCRP has been 
165 reported (Drozdzik et al., 2019; Drozdzik et al., 2014). Similarly, reported expression of BCRP in 
166 Caco-2 cells varieds greatly. MRP2 and MRP3 generally seemwere intermediately to highly expressed 
167 along the entire intestine (Akazawa et al., 2018; Drozdzik et al., 2019; Drozdzik et al., 2014; Gröer et 
168 al., 2013; Harwood et al., 2015) with a slight tendency of elevated expression in the colon (Drozdzik et 
169 al., 2019; Drozdzik et al., 2014). The expression of MRP2 in Caco-2 cells is was similar to the 
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170 expression in the small intestine (Brück et al., 2017; Uchida et al., 2015) with one exception, where 
171 lower expression was reported (Ölander et al., 2016). Ölander and co-workers quantified MRP3 in 
172 Caco-2 cells, and the expression of this protein was similar to the expression in the small intestine 
173 (Ölander et al., 2016). Brück et. al. and Uchida et. al. could not quantify MRP3 in Caco-2 cells (Brück 
174 et al., 2017; Uchida et al., 2015). 
175 Regarding carriers, PEPT1 exhibiteds high to very high expression in the small intestine (Akazawa et 
176 al., 2018; Drozdzik et al., 2019; Drozdzik et al., 2014; Gröer et al., 2013; Miyauchi et al., 2016), and 
177 increasing expression in the proximal to distal direction in the small intestine (Drozdzik et al., 2019; 
178 Drozdzik et al., 2014), however, the expression in the colon is was highly reduced (approx. 10- to 30-
179 fold) (Drozdzik et al., 2019; Drozdzik et al., 2014), (see Table 1). In Caco-2 cells, PEPT1 showeds 
180 different levels of expression from colon-like levels to small intestine-like levels (Brück et al., 2017; 
181 Uchida et al., 2015; Ölander et al., 2016) (Table 1). 
182 Absolute amounts of transporters and carriers in the human gastrointestinal tract highly depend on the 
183 site of sampling for the determination. Therefore, it is important to note that the site of sampling from 
184 anatomical structures varies between studies in the field (Drozdzik et al., 2019; Drozdzik et al., 2014; 
185 Lloret-Linares et al., 2016; Miyauchi et al., 2016). Additionally, tissue samples are occasionally only 
186 defined as ‘jejunal’, ‘ileal’, ‘distal jejunum’, or ‘distal ileum’ with no further definition (Akazawa et al., 
187 2018; Gröer et al., 2013; Harwood et al., 2015). Likewise, great inter-individual variation of intestinal 
188 transporter and carrier protein expression is likely, and we have left out all statistical deviation 
189 parameters in (Table 1) to enhance the overview. Moreover, protein expression is affected by external 
190 factors, for example certain drug compounds (Lin and Yamazaki, 2003) and dietary elements (Erickson 
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191 et al., 1995) along with general health condition and diseases (Englund et al., 2007; Wojtal et al., 
192 2009).
193 Finally, inter-laboratory variation is a well-documented factor, and we refer to the excellent cross-
194 laboratory study by Wegler and co-workers (Wegler et al., 2017). Herein, the authors have shown large 
195 variabilities, depending on the methods applied for quantification, especially when they compare 
196 whole-lysate and membrane fractionation techniques in the sample preparation. Depending on the drug 
197 formulation, pharmaceutical excipients, such as nonionic surfactants, are likely to be present at 
198 different concentrations in different segments of the intestine. To firmly understand how the excipients 
199 will affect drug absorption influenced by transporters or carriers, it is crucial to obtain more PBPK 
200 modelling knowledge regarding transporter and carrier expression patterns.
201
202 4. Nonionic surfactants modulate the transport activity of several ABC transporters 
203 4.1  Impact of nonionic surfactants on P-glycoprotein
204 The first discovered member of the ABC family, P-glycoprotein (Juliano and Ling, 1976), has until 
205 now been the most investigated transporter.  Since P-gp was found to mediate the cellular efflux of 
206 drug substances belonging to different drug classes, e.g. anticancer drugs and antibiotics, extensive 
207 research has been performed to modulate the transport activity of the transporter in vitro and in vivo. 
208 The next sections will focus on P-gp molecular characterization and substrate transport via P-gp, and 
209 cellular expression and tissue distribution of P-gp. In the subsequent sections, the effects of surfactants 
210 and co-surfactants on P-gp activity in vitro and on the intestinal absorption of P-gp substrates in vivo 
211 will be discussed. 
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212 P-glycoprotein molecular characterization and substrate transport
213 P-glycoprotein is a 170 kDa efflux transporter that requires energy from ATP hydrolysis to pump 
214 substrates out or across cellular membranes. It has been estimated that P-gp requires two ATP 
215 molecules to transport one substrate (Ambudkar et al., 1997; Sauna and Ambudkar, 2001). Due to the 
216 direct use of ATP, the transporter is able to transport its substrates against the concentration gradient, 
217 and therefore P-gp can limit the cellular accumulation and retention of certain drug substances. In 
218 human, P-gp is expressed in the cell membrane in different tissues such as the luminal membrane in 
219 enterocytes, the canalicular membrane in hepatocytes, in the luminal membrane in proximal tubular 
220 cell, in the luminal membrane of endothelial cells of the central nervous system and testes, bronchial 
221 cells of lungs, and placenta (Cordon-Cardo et al., 1990), hence affecting the ADMET properties of its 
222 substrates. P-gp substrates include a wide range of hydrophobic and amphipathic substrates such as 
223 drug substances and toxins with diverse molecular weight ranging from approximately 300-4000 Da 
224 (Fromm, 2004; Rao et al., 1999; Su et al., 2009). Hundreds of drug substances are P-gp substrates 
225 (Drugbank, 2019) including anti-cancer drugs, antibiotics, cardiac drugs, immuno-suppressants, lipid-
226 lowering agents, HIV drugs, and hormones (Chan et al., 2004; Fromm, 2004; Seelig, 1998). 
227 It has previously been suggested that P-gp substrates might diffuse through the membrane bilayer and 
228 reach the cytoplasmic leaflet, where the substrate gets access to the protein (Raviv et al., 1990). P-gp 
229 will then according to this mechanistic proposal act as a hydrophobic “vacuum cleaner” that pumps the 
230 substrate to the extracellular environment (Raviv et al., 1990). Another model referred as “flippase 
231 model” assumed that the P-gp substrate first partition into the lipid bilayer and reach the inner leaflet, 
232 where the substrate has access to P-gp. At this stage, the substrate will be pumped directly to the 
233 extracellular environment by P-gp or flipped by the protein to the outer leaflet of the lipid bilayer 
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234 (Higgins and Gottesman, 1992). In both cases, the movement of the substrate would be driven by either 
235 the equilibrium between the concentration of the substrate in the extracellular environment and in the 
236 outer leaflet, or between the concentration of the substrate in the inner leaflet and in the cytoplasm 
237 (Higgins and Gottesman, 1992). There is accumulating evidence supporting the flippase model for P-gp 
238 mediated substrate transport across the membrane bilayer (Abulrob and Gumbleton, 1999; Eckford and 
239 Sharom, 2005; Romsicki and Sharom, 2001; van Helvoort et al., 1996).  
240 It was proposed that the transmembrane (TM) organization of P-gp consists of two TM domains (Chen 
241 et al., 1986). , which eEach domain has six TM helices and one nucleotide-binding domain (NBD) 
242 located in the cytoplasm (Fig. 1a) (Chen et al., 1986) (Fig. 1a). Recently, the inward-facing 
243 conformation of mouse P-gp proposed that the TM helices are arranged to form an internal cavity of 
244 approximately 6000 Å3, which is integrated in the lipid bilayer (Aller et al., 2009). It has been 
245 suggested that P-gp might have portals open to the cytoplasmic region and to the inner leaflet of the 
246 lipid bilayer (Aller et al., 2009). The P-gp substrates may therefore via these portals get access to the 
247 binding sites in the internal cavity of the P-gp, where two P-gp substrates could simultaneously be 
248 accommodated (Aller et al., 2009). By using cryo-electron microscopy at 3.4 Å resolution, recent 
249 research has also shown the outward-facing conformation of human P-gp (Kim and Chen, 2018). In 
250 brief, a P-gp substrate may bind to the internal cavity of the inward-facing conformation of P-gp, as it 
251 has been suggested by Aller and co-workers (Aller et al., 2009), and this initiates ATP binding to the 
252 NBDs of the protein (Kim and Chen, 2018). In the process of reaching the outward-facing 
253 confirmation, the NBDs may dimerize resulting in the NBD’s becoming closer, while the TM helices 
254 re-arrange toward the extracellular space and compress, preventing the binding of the substrate to P-gp 
255 (Kim and Chen, 2018) (Fig. 1a). In its outward-facing confirmation, the extracellular part of TM 
256 helices seems to be flexible for the substrate release and transport to the extracellular environment. 
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257 ATP hydrolysis will then reset the P-gp to the inward-facing conformation (Kim and Chen, 2018). as it 
258 has been illustrated for the mouse P-gp (Aller et al., 2009). The inward- and outward-facing 
259 conformations of P-gp which were proposed to occur during the substrates translocation may support 
260 that the substrates transport across the membrane bilayer most likely occur by the flippase model. 
261
262 4.1.1 Nonionic surfactants inhibit P-glycoprotein in vitro via different mechanisms
263
264 The most investigated nonionic surfactants that inhibit P-gp transport in vitro are cremophor® EL, 
265 Solutol® HS 15, TPGS 1000, polysorbate 20, polysorbate 80 and pluronic® P85, (see Table 2). Several 
266 in vitro assays have been utilized to investigate the P-gp inhibitory properties of these surfactants 
267 including: 1) measuring the impact of surfactants on substrate absorptive and/or secretory transport 
268 using cell-based systems or intestinal segments excised from animals, 2) measuring the ATPase activity 
269 of P-gp using membrane vesicles from cells overexpressing P-gp, and 3) fluorescence-based (e.g. 
270 calcein-AM) efflux assay using cells highly overexpressinged with P-gp. In bi-directional transport 
271 assays, nonionic surfactants were shown to enhance the absorptive permeability of model P-gp 
272 substrates such as digoxin (Al-Ali et al., 2018b; Batrakova et al., 2001; Collnot et al., 2010; Nielsen et 
273 al., 2016) and rhodamine 123 (Collnot et al., 2010; Guan et al., 2011; Kiss et al., 2014; Rege et al., 
274 2002; Sachs-Barrable et al., 2007; Zhao et al., 2016), and to decrease the secretory permeability of 
275 these substrates across cell monolayers. Consequently, the data presented in Table 2 strongly support 
276 that these surfactants inhibit the efflux activity of P-gp, thus provide a promising approach to inhibit P-
277 gp-mediated efflux of drug substances. In addition, Table S1 provides a comprehensive overview of 
278 many other nonionic surfactants and co-surfactants that have shown different abilities to inhibit P-gp-
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279 mediated transport in vitro. The results provided in this table may assist providing an overview of 
280 likely interactions.
281 Different mechanisms have been proposed to explain the mechanisms behind how nonionic surfactants 
282 increase drug absorption by inhibiting P-gp-mediated cellular efflux (see Fig. 2). Work from Seelig and 
283 co-worker has suggested that the inhibition may occur through partitioning of the hydrophobic tail of 
284 the surfactant into the cell membrane, while the hydrogen bond acceptor groups in the hydrophilic 
285 moiety of the surfactant form hydrogen bonds with the hydrogen bond donor groups in the TM domain 
286 of the protein (Li-Blatter et al., 2009; Seelig and Gerebtzoff, 2006), (Fig. 2). These hydrogen bonds 
287 between the surfactant and the TM domain in P-gp may explain the higher affinity of surfactants with 
288 large number of hydrogen bond acceptor groups such as n-octyl-β-D-maltopyranoside (C8-malt) and 3-
289 cyclohexyl-1-propyl-β-D-maltopyranoside (Cymal-3), than surfactants with fewer hydrogen bond 
290 acceptor groups e.g. n-heptyl-β-D-glucopyranoside (C7-gluc). Thus C8-malt and Cymal-3 with a similar 
291 number of hydrogen bond acceptor groups exhibit almost the same affinity to the membrane as C7-gluc, 
292 but a higher affinity to the P-gp protein, due to the duplication of the sugar moiety in maltopyranoside 
293 based-surfactants compared to the single sugar moiety in glucopyranoside (Li-Blatter et al., 2012; Li-
294 Blatter et al., 2009; Li-Blatter and Seelig, 2010; Xu et al., 2015). This observation may be supported by 
295 the results from a recent study (Al-Ali et al., 2018b), which reported that polysorbate 20 elicited higher 
296 affinity to P-gp in the calcein-AM efflux assay than the mono-saccharide based surfactants, e.g. lauroyl 
297 methyl glucamide, and the di-saccharides based surfactants, e.g. lauryl-β-D-maltoside, since the former 
298 surfactant had a higher number of hydrogen acceptor groups when retaining the laurate side chain in 
299 the surfactants (Al-Ali et al., 2018b). The latter study also suggested that extending the alkyl side chain 
300 to more than laurate e.g. stearate in polysorbate 60 and oleate in polysorbate 80, or attaching multiple 
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301 alkyl groups such as tri-stearate in polysorbate 65, while retaining the hydrophilic group in these 
302 surfactants, may decrease the affinity of the surfactant to P-gp (Al-Ali et al., 2018b). Therefore, the 
303 study concluded that in vitro both the hydrophobic and hydrophilic moieties in nonionic surfactant may 
304 contribute to the surfactant mediated P-gp inhibition.
305 The second proposed mechanism of P-gp inhibition by nonionic surfactants relates to the alteration of 
306 membrane bilayer fluidity induced by surfactants, an alteration that might indirectly inhibit the ATPase 
307 activity (Fig. 2). It was shown that polysorbate 20, Nonidet™ P-40 and Triton™ X-100, which all 
308 increase the fluidity of artificial membranes, inhibited P-gp ATPase activity in membrane vesicles 
309 prepared from Chinese hamster ovary AA8 cells (Regev et al., 1999), (Table 2). In addition, it was 
310 reported that polysorbate 80 and cremophor® EL, which increased membrane fluidity significantly, also 
311 inhibited P-gp. The inhibition resulted in a significant increase in the absorptive permeability across 
312 Caco-2 cells of the model P-gp substrate rhodamine 123 and a significant decrease in the secretory 
313 permeability (Rege et al., 2002). In a subsequent study, the surfactant N-octyl glucoside did not 
314 modulate membrane bilayer fluidity and did not change the absorptive and secretory permeability of 
315 rhodamine 123 (Rege et al., 2002).  
316 Wei and co-workers proposed that the intracellular depletion of ATP was the main mechanism of P-gp 
317 inhibition by pluronic-based surfactants such as pluronic® P123 suggesting a third mechanism of P-gp 
318 inhibition (Wei et al., 2010; Wei et al., 2013), (see Fig. 2). This third suggested mechanism of P-gp 
319 inhibition is supported by previous studies which reported that pluronic® P85 and pluronic® L64 
320 enhanced the intracellular accumulation of the P-gp substrate rhodamine 123 and decreased 
321 intracellular ATP in vitro (Batrakova et al., 2003a), (Table 2). 
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322 The fourth proposed mechanism of surfactant mediated P-gp inhibition suggested a combined effect of 
323 depleted intracellular ATP and alteration in cellular membrane fluidity (Batrakova et al., 2003a; 
324 Batrakova et al., 2003b), (see Fig. 2). In support of this, it was reported that pluronic® P85 and 
325 pluronic® L81, which enhanced membrane fluidity, were able to deplete the intracellular ATP, and 
326 significantly enhanced the intracellular accumulation of rhodamine 123 in bovine brain microvessel 
327 endothelial cells (Batrakova et al., 2003b; Batrakova et al., 2004), (Table S1). 
328 Consequently, the mechanisms of P-gp inhibition by surfactants seem complex. It could be that one or 
329 more mechanisms or more are involved in such inhibition. However, further research focused on 
330 further characterizing the underlying mechanism(s) of surfactant-mediated P-gp inhibition is needed, 
331 which might assist in choosing the appropriate surfactant(s) or developing new surfactant(s) that could 
332 be more potent than the ones available and perhaps transporter specific.   
333 4.1.24.1.1 Surfactants used in preparing lipid-based formulations may inhibit 
334 P-glycoprotein in vitro 
335 Surfactants can be used in pharmaceutical formulations such as lipid-based formulations (LBF) 
336 (Pouton, 2006). Currently, many drug substances available in the market are incorporated into LBFs 
337 such as tipranavir (Aptivus®), bexarotene (Targretin®), and sirolimus (Rapamune®), where the 
338 surfactants function as solubilizing agents and emulsifiers (Savla et al., 2017). For formulations of P-gp 
339 substrates, inclusion of surfactants that have P-gp inhibition properties might be advantageous with 
340 respect to enhancement of substrate transport across biological membranes. Therefore, studies have 
341 reported the use of the LBFs to enhance the oral absorption of different P-gp substrates (Akhtar et al., 
342 2015; Zhao et al., 2013). The self-micro-emulsifying drug delivery systems (SMEDDS) containing 
  
17
343 cremophor® RH 40, cremophor® EL, or polysorbate 80 (Zhao et al., 2013), and the self-nano-
344 emulsifying drug delivery systems (SNEDDS) containing cremophor® RH40 and Transcutol® P 
345 (Akhtar et al., 2015) were shown to enhance etoposide permeability across intestinal tissues and cell 
346 monolayers partly due to the inhibition of P-gp by these surfactants. In human, several studies showed 
347 enhanced oral absorption of the P-gp substrate cyclosporine A when formulated in LBFs compared to 
348 the oral absorption of cyclosporine A from conventional oral dosage forms (Bekerman et al., 2004; 
349 Drewe et al., 1992; Postolache et al., 2002). Cyclosporine A is an immunosuppressant used in 
350 prophylaxis and treatment of graft rejection in organ transplantations, and in treatment of autoimmune 
351 diseases e.g. rheumatoid arthritis, aplastic anemia, and myasthenia gravis (Italia et al., 2006). 
352 Cyclosporine A has low aqueous solubility (0.04 mg mL-1) (O'Leary et al., 1986), low permeability in 
353 cell cultures (Augustijns et al., 1993; Fricker et al., 1996), and high variations in oral bioavailability 
354 among patients (Czogalla, 2009; Lown, 1997). In the studies where cyclosporine A was prepared in 
355 LBFs (Bekerman et al., 2004; Drewe et al., 1992; Postolache et al., 2002), the possible P-gp inhibition 
356 effect of excipients, e.g. nonionic surfactants, was however not mentioned. Interestingly, the excipients 
357 used to prepare LBFs-containing cyclosporine A were polysorbate 80, cremophor RH 40 (Bekerman et 
358 al., 2004), sucrose monolaurate, hydrogenated castor oil, and polyethylene glycol (Drewe et al., 1992), 
359 which were later shown to possess P-gp inhibitory properties in vitro (Al-Ali et al., 2018a; Al-Saraf et 
360 al., 2016; Ashiru-Oredope et al., 2011; Chiu et al., 2003; Cornaire et al., 2004; Gurjar et al., 2018; 
361 Hanke et al., 2010; Hodaei et al., 2015; Hugger et al., 2002; Johnson et al., 2002; Kiss et al., 2014; 
362 Rege et al., 2002; Shono et al., 2004) (Table 2 and S1), and/or in vivo  (Shimomura et al., 2016; Zhang 
363 et al., 2003; Zhao et al., 2013) (Table 3).
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364 Furthermore, previous research have reported that several surfactants such as lauroyl methyl 
365 glucamide, lauryl-β-D-maltoside, and trehalose 6-laurate that inhibited the efflux of P-gp substrate 
366 calcein-AM in MDCKII MDR1 cells, (Table S1), might also possess paraceullar and/or transcellular 
367 permeation enhancing effects in cell cultures (Al-Ali et al., 2018b; Eley and Triumalashetty, 2001; 
368 Petersen et al., 2012). Such effects might be advantageous when designing LBFs to enhance the oral 
369 absorption of P-gp substrate drug substances with limited oral bioavailability induced by intestinal P-
370 gp. 
371 Additionally, the mixed micelles formulations such as pluronic® 105/pluronic® F-127, pluronic® 
372 P123/pPluronic® F127, and polysorbate 80/pluronic® F-127 were shown to inhibit the P-gp-mediated 
373 efflux of docetaxel (Chen et al., 2013), paclitaxel (Wei et al., 2010), and morin (Choi et al., 2015), 
374 respectively, in cells highly over expressing P-gp (Table S1). Despite the fact, that pluronic® F-127 was 
375 used in the latter formulations and proposed to inhibit P-gp in another study (Guan et al., 2011), several 
376 studies reported that pluronic® F-127 did not inhibit P-gp mediated efflux of several P-gp substrates 
377 e.g.such as rhodamine 123 (Batrakova et al., 2003b; Wei et al., 2013), nelfinavir (Shaik et al., 2008), 
378 etoposide (Al-Ali et al., 2018a), and digoxin (Gurjar et al., 2018). In these types of formulations, one 
379 limitation could be that the drug substances might also be adsorbed to the core of surfactant micelles, 
380 which may decrease the free fraction of unbound substrate in the formulation, thus affecting the 
381 subsequent oral absorption and bioavailability of the substrate in vivo. Therefore, investigating the 
382 release of drug substances from micelles is important and should be performed in vitro in order to 
383 avoid or understand such impacts of surfactants in vivo. The LBFs containing nonionic surfactants that 
384 have P-gp inhibitory properties seem, however, as a promising approach to improve P-gp substrates 
385 permeability across cellular membranes.
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386 4.1.34.1.2 Nonionic surfactants inhibited P-glycoprotein in vitro at below and 
387 above critical micelle concentrations
388 In several studies performed in cell cultures, it was observed that the inhibition of P-gp transport 
389 activity by nonionic surfactants decreased at concentrations at or above the surfactants critical micelles 
390 concentration (CMC) compared to concentration below CMC. It was reported that pluronic® P85 
391 (Batrakova et al., 2003b; Batrakova et al., 2004), cremophor® EL (Shono et al., 2004), and polysorbate 
392 40 (Zhu et al., 2009) were effective in inhibiting P-gp transport activity at concentrations lower than 
393 their CMCs in vitro; however, this inhibitory effect decreased at or above the surfactants CMC values 
394 (Batrakova et al., 2003a; Batrakova et al., 2003b; Batrakova et al., 2004; Shono et al., 2004; Zhu et al., 
395 2009) (Table 2 and S1). A possible explanation to this observation could be that most P-gp substrates 
396 are lipophilic substances, which after incorporation into the hydrophobic core of micelles, lead to a 
397 decrease in the unbound fraction of the substrate available for the transcellular transport, and hence the 
398 observed reduction in substrate transport, termed the solubility/permeability interplay (Beig et al., 
399 2017; Beig et al., 2015; Dahan et al., 2010; Miller et al., 2011). 
400 In addition, using the parallel artificial membrane permeability assay (PAMPA), the passive 
401 permeability of the P-gp substrate paclitaxel across artificial membranes have been shown to decrease 
402 significantly when the TPGS 1000 concentration in the donor chamber was above the CMC (Varma 
403 and Panchagnula, 2005). Furthermore, using PAMPA, increasing the concentration of the surfactants 
404 such as sodium lauryl sulfate above the CMC values decreased the passive permeability of etoposide 
405 across artificial membranes (Beig et al., 2015). The PAMPA studies may support the hypothesis that 
406 the decreased permeability of the substrates was related to the incorporation of paclitaxel and etoposide 
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407 in the micelles, this may support the effect of surfactant on the thermodynamic activity of the substrate 
408 rather than the decreased inhibitory effect of surfactant above the CMC. 
409 Moreover, many studies have reported that nonionic surfactants, used at concentrations above their 
410 CMCs, inhibited the efflux of P-gp substrates in vitro such as (Surfactant: P-gp substrate/s): 
411 (cremophor® RH 40: rhodamine 123) (Kiss et al., 2014), (Brij® 58: digoxin and rhodamine 123) 
412 (Gurjar et al., 2018; Zhao et al., 2016), (cremophor® EL: etoposide and digoxin) (Al-Ali et al., 2018a; 
413 Gurjar et al., 2018), (Labrasol®: rhodamine 123) (Lin et al., 2007), and (polysorbate 20: etoposide, 
414 doxorubicin, digoxin, and epirubicin) (Al-Ali et al., 2018b; Al-Saraf et al., 2016; Gurjar et al., 2018; 
415 Lo, 2003). Consequently, it seems that nonionic surfactants at concentration higher than their CMC 
416 values are able to inhibit P-gp in vitro; however, care should be taken in the interpretation due to the 
417 potential influence for of the solubility/permeability interplay.
418 4.1.44.1.3 Polyethylene glycol (PEG) derivatives inhibited P-glycoprotein in 
419 vitro 
420 In addition to nonionic surfactants, co-surfactants such as polyethylene glycol (PEG) derivatives are 
421 used in a broad spectrum of drug delivery systems where these excipients are used as solubilizers, 
422 stabilizers, release-modifiers, and bioavailability enhancers (D'Souza and Shegokar, 2016). From Table 
423 2 and S1, it can be noticed that several PEG derivatives with different molecular weight including PEG 
424 300, PEG 400, PEG 2000, PEG 6000, and PEG 20000 were reported to decrease the efflux of several 
425 P-gp substrates in Caco-2 cells and in rat intestinal segments. In vitro, it has been shown that PEG 400 
426 at concentration of 0.1-20% (w/v, or v/v) may decrease the efflux of several P-gp substrates e.g. 
427 digoxin (Johnson et al., 2002), ranitidine (Ashiru-Oredope et al., 2011), and rhodamine 123 (Hodaei et 
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428 al., 2015; Shen et al., 2006). Furthermore, recent studies have reported that PEG 400 may decrease the 
429 P-gp expression in Caco-2 cells (Hodaei et al., 2015) and increase the P-gp ATPase activity (Ashiru-
430 Oredope et al., 2011), suggesting two different mechanism of P-gp inhibition. The latter effect might 
431 refer to the direct interaction of PEG 400 with P-gp, thus competitively inhibited the protein (Ashiru-
432 Oredope et al., 2011). Moreover, PEG 300 was reported to inhibit P-gp through altering Caco-2 
433 membrane fluidity (Hugger et al., 2002), suggesting a third mechanism of PEG derivatives mediated P-
434 gp inhibition in vitro. 
435 4.1.54.1.4 Nonionic surfactants increased the oral absorption of P-glycoprotein 
436 substrates in vivo
437 The impact of nonionic surfactants on the oral absorption of P-gp substrates have mainly been 
438 investigated in wild type rats, (Table 3). Several surfactants such as polysorbate 20 and 80 have been 
439 shown to increase the oral absorption of different P-gp substrates such as polysorbate 80, which has 
440 been shown to enhance the oral absorption of such as digoxin (Zhang et al., 2003), etoposide (Zhao et 
441 al., 2013), and rifampicin (Shimomura et al., 2016). The concentrations of surfactants that increased the 
442 oral absorption of different P-gp substrates range from 1-25% (w/v), (see Table 3). Recently, wild type 
443 and mdr1a deficient rats have been used to investigate the role of intestinal P-gp for the oral absorption 
444 of digoxin (Nielsen et al., 2016) and etoposide (Al-Ali et al., 2018a). In these studies, there was 
445 approximately 2- and 8-fold increase in the AUC of digoxin and etoposide, respectively, in mdr1a 
446 deficient rats compared to wild type rats. When 5% and 10-25 % (v/v) polysorbate 20 was co-
447 administered with etoposide and digoxin, respectively, in wild type rats, the oral bioavailability was 
448 enhanced significantly. However, in mdr1a deficient rats, the presence or absence of similar doses of 
449 the surfactant did not influence the bioavailability indicating that the enhanced oral absorption in the 
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450 wild type rats was most likely related to P-gp inhibition effects mediated by polysorbate 20 rather than 
451 enhancement of the substrate solubility by the surfactant. 
452 In relation to scaling between in vitro and in vivo studies of the surfactants, it has been shown that a 
453 concentration of  20-500 µM polysorbate 20 decreased the efflux ratio of digoxin and etoposide in cell 
454 cultures (Al-Ali et al., 2018a; Nielsen et al., 2016), whereas  in pre-clinical studies, in wild type rats, 
455 the minimum doses of polysorbate 20 required to increase the oral bioavailability of digoxin (Nielsen et 
456 al., 2016) and etoposide (Al-Ali et al., 2018a) were 10% (v/v, 90 mM) and 5% (v/v, 45 mM), 
457 respectively. However, in mdr1a deficient rats, it was noticed that the oral absorption and 
458 bioavailability of etoposide decreased when co-administered with 25% (v/v) polysorbate 20 compared 
459 to the oral absorption with 0 or 5% (v/v) polysorbate 20, or without the surfactant (Al-Ali et al., 2018a). 
460 In vitro dialysis studies demonstrated that etoposide release from a 25% polysorbate 20 containing 
461 formulation was minimal, most likely due to the incorporation of etoposide into the micelles formed by 
462 the polysorbate (Al-Ali et al., 2018a). Furthermore, it has been reported that 5% labrasol® increased the 
463 oral bioavailability of etoposide more when co-administered with 5% labrasol® than with 10% 
464 labrasol® (Akhtar et al., 2017), indicating that etoposide release from the micelles was concentration 
465 dependent (Akhtar et al., 2017), (see also Table 3).
466 TPGS 1000 enhanced the oral bioavailability of paclitaxel in wild type rats with a factor of six relative 
467 to the bioavailability when administered without the surfactant (control) (Varma and Panchagnula, 
468 2005), (Table 3). Verapamil was further demonstrated to enhance the oral bioavailability of similar 
469 doses of paclitaxel four times compared to control (Varma and Panchagnula, 2005). With respect to the 
470 use of surfactants in vivo, it should be noted that some of these surfactants undergo digestion in the 
471 intestinal tract (Christiansen et al., 2010; Cuiné et al., 2008; Devraj et al., 2013; Mohsin, 2012), why 
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472 and might thus be less efficient the use of these relative tothan small-molecular P-gp inhibitors like 
473 verapamil, should be considered with respect to the hypothesis of the studies.
474 From Table 2, 3 and S1, it is evident that research is still needed to establish how inhibition observed in 
475 vitro translates into increased absorption in vivo, since many nonionic surfactants such as Brij® 78, 
476 pluronic® P123, and polysorbate 40, have not yet been investigated for their abilities to inhibit 
477 intestinal P-gp in vivo. Moreover, for some surfactants that were extensively investigated in vitro such 
478 as cremophor® EL, pluronic® 85 and Solutol® HS 15, (see also Table 2), only few in vivo studies have  
479 reported the effect on PK of these surfactants on PK in animals (Bittner et al., 2002; Föger et al., 2006; 
480 Zhao et al., 2013), (Table 3). Consequently, further in vivo studies are needed to advance the 
481 knowledge about the effect of these surfactants on the oral absorption of different P-gp substrates, 
482 which may assist in designing and performing clinical studies in humans. 
483
484 4.2 Impact of nonionic surfactants on breast cancer resistance protein
485 The ABC transporter BCRP is as a monomeric protein of 72 kDa (Doyle and Ross, 2003; Mao, 2005) 
486 consisting of one TM domain of six TM helices, and one NBD located in the cytoplasm (Chen et al., 
487 2015; Mao and Unadkat, 2015; Wang et al., 2008). Two BCRP monomers dimerize to form a 
488 functional BCRP transporter (Fig. 1b) (Rosenberg et al., 2010; Rosenberg et al., 2015). The helices are 
489 arranged to form a cavity, where BCRP substrates bind, while TM helices one and six are attached to 
490 amino and carboxyl termini in the cytoplasm, respectively (Wang et al., 2008). BCRP substrates belong 
491 to different therapeutic classes such as anticancer drugs, HIV drugs, antihistamines, and anti-
492 hyperlipidemia drugs (Mao and Unadkat, 2015). BCRP shares many substrates with P-gp e.g. 
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493 topotecan (Jonker et al., 2000; Maliepaard et al., 1999), doxorubicin (Allen et al., 1999; Mechetner et 
494 al., 1998), irinotecan (Gupta et al., 1996; Maliepaard et al., 1999), and etoposide (Allen et al., 2003; 
495 Keller et al., 1992). In humans, BCRP is highly expressed in normal tissues such as the apical 
496 membrane of small intestinal and colonic enterocytes, canalicular membranes in the liver, endothelial 
497 cells of brain microvessels (Mao, 2005), veins and capillaries, and in cancer cells (Doyle and Ross, 
498 2003; Maliepaard et al., 2001b). Since BCRP is expressed in different tissues, its modulation in humans 
499 may influence the ADMET properties of its substrates. In the past, BCRP inhibitors were developed to 
500 overcome the multidrug resistance phenomenon, as well as to enhance the oral absorption of the 
501 substrates (Gupta et al., 2006; Gupta et al., 2004; Houghton et al., 2004; Matsson et al., 2009). BCRP 
502 inhibitors may act as competitive inhibitors at the substrate binding sites, as allosteric inhibitors by 
503 binding to the protein at a site different from the substrate binding site in the BCRP cavity, or by 
504 inhibiting ATPase activity (Mao and Unadkat, 2015). Of the BCRP inhibitors identified; some of these 
505 also inhibit P-gp e.g. GF120918, and the tyrosine kinase inhibitors imatinib, and the antifungal drug 
506 substance itraconazole (Mao and Unadkat, 2015; Matsson et al., 2009). 
507 Until now, few sStudies were performed by Yamagata and co-workersto have investigateding the effect 
508 of nonionic surfactants on BCRP transport activity in vitro and in vivo (Sawangrat et al., 2018a; 
509 Sawangrat et al., 2018b; Xiao et al., 2016; Xu et al., 2015; Yamagata et al., 2007a, b; Yamagata et al., 
510 2009). In MDCKII BCRP cells, nonionic surfactants such as cremophor® EL, polysorbate 20, span 20, 
511 pluronic® P85, and Brij® 30 increased the uptake of the BCRP substrate mitoxantrone (Yamagata et al., 
512 2007a) (Table 4). Yamagata and coworkers were also able to enhance the uptake of mitoxantrone in 
513 MDCKII MDR1 by the use of the same surfactants indicating the ability of these surfactants to 
514 modulate both BCRP and P-gp (Yamagata et al., 2007a), effects that wasere demonstrated both in vitro 
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515 (Al-Ali et al., 2018a; Al-Ali et al., 2018b; Al-Saraf et al., 2016; Gurjar et al., 2018; Li-Blatter and 
516 Seelig, 2010; Lo, 2003; Nielsen et al., 2016; Rege et al., 2002; Shaik et al., 2008), and in vivo (Al-Ali 
517 et al., 2018a; Föger et al., 2006; Nielsen et al., 2016; Zhao et al., 2013), for further details see (see 
518 Table 2, 3 and S1). With respect to the effect of nonionic surfactants on BCRP, it another study was 
519 reported that pluronic® P85 and polysorbate 20 enhanced the mucosal-to-serosalM-S transport of 
520 BCRP substrate topotecan across ileum everted sacs derived from wild type mice (see Table 4) 
521 (Yamagata et al., 2007b). Interestingly, in everted intestinal sacs derived from Abcg2 deficient mice, 
522 topotecan absorption rate was significantly enhanced in comparison to the absorption rate in everted 
523 intestinal sacs from wild type mice (Yamagata et al., 2007b). However, the presence of surfactants did 
524 not further improve the absorption rate of topotecan in Abcg2 deficient everted intestinal sacs, 
525 demonstrating the surfactants’ impacts in mediating the Bcrp inhibition in the wild type animals 
526 (Yamagata et al., 2007b). In vivo, pluronic® P85 and polysorbate 20 administered orally 15 min before 
527 oral administration of topotecan to wild type mice increased the AUC of topotecan significantly, when 
528 compared to the administration of similar doses of topotecan without the surfactant (Yamagata et al., 
529 2007b). It was later noticed that the interaction of pluronic® P85 and polysorbate 20 with Bcrp was 
530 reversible and transient upon removal of these surfactants (Yamagata et al., 2009). It is worth noticing 
531 that these surfactants were also able to inhibit P-gp in vitro (Al-Ali et al., 2018a; Al-Ali et al., 2018b; 
532 Al-Saraf et al., 2016; Batrakova et al., 2003a; Batrakova et al., 2004; Gurjar et al., 2018; Nielsen et al., 
533 2016; Shaik et al., 2008) (Table 2, S1) and in vivo (Al-Ali et al., 2018a; Föger et al., 2006; Nielsen et 
534 al., 2016) (Table 3). 
535 Moreover, Rrecent research has reported that several surfactants, including 6-tetradecyl-β-D-
536 maltopyranoside, (C6-malt) (Xu et al., 2015), cremophor® EL (Al-Ali et al., 2018a; Al-Saraf et al., 
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537 2016; Gurjar et al., 2018; Rege et al., 2002; Shono et al., 2004), BL-9EX, Brij® 92, Brij® 97 (Zhao et 
538 al., 2016), and labrasol® (Akhtar et al., 2017; Cornaire et al., 2004; Lin et al., 2007; Ma et al., 2011), 
539 which have been shown to inhibit P-gp (Table 2), have also been able to inhibit BCRP in MDCKII 
540 BCRP cells (Xiao et al., 2016), in membrane vesicles containing human BCRP (Xu et al., 2015), and 
541 Bcrp in rat intestinal membrane and in vivo using the in situ closed intestinal loop method (Sawangrat 
542 et al., 2018a). The doses of the surfactants used to inhibit BCRP in vitro and in vivo (Sawangrat et al., 
543 2018a; Xiao et al., 2016; Xu et al., 2015) were comparable to the doses used to inhibit P-gp (Akhtar et 
544 al., 2017; Lin et al., 2007; Ma et al., 2011; Zhao et al., 2016) (Table 2, 3, and S1). As similar doses of 
545 nonionic surfactants appeared to be able to inhibit P-gp and BCRP, and since many drug substances 
546 that are BCRP substrates share substrate specificity with P-gp, drug formulators should thus consider 
547 the surfactants used in their formulations, and avoid using the surfactants that may have overlap in 
548 inhibiting effect on both transporters in cases where this may have an influence on the 
549 biopharmaceutical properties of the compoundsubstrate. Cremophor® EL was shown to enhance the 
550 absorptive permeability and decrease the secretory permeability of scutellarin in MDCKII BCRP (Xiao 
551 et al., 2016). Scutellarin is a flavonoid glucuronide approved in China to treat patients with cerebral 
552 infarction and paralysis caused by cerebrovascular diseases (Xiao et al 2016). In wild type rats, 
553 cremophor® EL enhanced scutellarin oral absorption, however, this study also reported that the 
554 surfactant affected other transporters such as MRP2 and MRP3 (See section 4.3). Another recent study 
555 by Sawangrat and co-workers showed that 0.05 % (w/v) cremophor® EL enhanced the absorptive 
556 permeability and decreased the secretory permeability of topotecan significantly in Caco-2 cells, and 
557 enhanced the intestinal absorption of topotecan in rats using the in situ closed-loop method (Sawangrat 
558 et al., 2018b). Similar concentration of cremophor® EL did, however, not influence the absorptive or 
559 secretory permeability of the BCRP substrate sulfasalazine across rat intestinal segments in diffusion 
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560 chambers (Sawangrat et al., 2018a). Furthermore, using the in situ closed-loop method, 0.05% (w/v) 
561 polysorbate 20 enhanced the intestinal absorption of topotecan significantly in rats (Sawangrat et al., 
562 2018b). In contrast; however, higher concentration (0.1 and 0.5% w/v) of the surfactant did not 
563 enhance the absorption of sulfasalazine in another study (Sawangrat et al., 2018a). The effect of 
564 nonionic surfactants on the transport of BCRP substrates across the intestine therefore seems to differ 
565 as a function of substrate and/or method used. Further studies are needed to investigate the effects of 
566 nonionic surfactants on the transport activity of BCRP in vitro and in vivo. It is recommended that 
567 different BCRP substrates and different methods are used in the prospective investigations.  
568
569 4.3 Impact of nonionic surfactants on the multidrug resistance-associated protein 2 
570 In human tissues, the efflux transporter multidrug resistance-associated protein 2 (MRP2) is expressed 
571 in the hepatocyte canalicular membrane, gallbladder epithelial cells, the proximal tubule of the kidney, 
572 duodenum, jejunum, ileum, brain, bronchi, and placenta (Jedlitschky et al., 2006; Kool et al., 1997; 
573 Nies and Keppler, 2007). MRP2 is highly expressed in cancer cells, such as non-small cell lung cancer 
574 and adeno-lung carcinoma (Kool et al., 1997). MRP2 consists of two TM domains, each has six TM 
575 helices, linked intracellularly with two NBDs located in the cytoplasm (Fig. 1c) (Jedlitschky et al., 
576 2006). To the NBDs, ATP molecules bind, which is required for hydrolysis initiating substrate 
577 transport (Jedlitschky et al., 2006). In addition, a third TM domain consisting of five helices is attached 
578 to the first TM domain via a linker (L0), which is located in the cytoplasm. The third TM domain is 
579 extracellularly attached to NH2 terminus of the first TM domain (see Fig. 1c) (Jedlitschky et al., 2006). 
580 MRP2 transports different endogenous compounds such as glutathione, leukotrienes, bilirubin 
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581 glucuronides and steroids, and drug substances of different classes, e.g. anticancer drugs, HIV drugs, 
582 antibiotics, and the metabolites of these substances (Dietrich et al., 2003; Jedlitschky et al., 2006).  
583 The effect of nonionic surfactants on MRP2 has been investigated in vitro using different assays, e.g. 
584 bi-directional transport, uptake assay, ATP measurements, and phosphate release measurements. It was 
585 reported that pluronic® P85 enhanced the intracellular accumulation of the MRP2 substrates vincristine 
586 and doxorubicin in MDCKII MRP2 cells (Batrakova et al., 2003a). This was confirmed by decreased 
587 ATP levels in MDCKII MRP2 cells and decreased ATPase activity in the membrane vesicles isolated 
588 from these cells (Batrakova et al., 2004). Based upon these data, Batrakova and co-workers proposed 
589 that the mechanism of MRP2 inhibition could be related to the change in membrane fluidity or binding 
590 of the surfactant to the cell membrane, thereby competitively preventing the drug-protein interaction 
591 (Batrakova et al., 2004). Beside the effect of pluronic® P85 on MRP2, it was found that similar 
592 concentrations of the surfactant inhibited MRP1 and P-gp (Batrakova et al., 2004). 
593 Recent studies have shown that surfactants including cremophor® EL, cremophor® RH 40, pluronic® 
594 F68, and pluronic® P-127, and co-surfactants PEG 400, and PEG 2000 decreased the efflux ratio of the 
595 MRP2 substrate scutellarin in Caco-2 cells (Li et al 2013, Li et al 2014). Scutellarin is a flavonoid 
596 glucuronide approved in China to treat patients with cerebral infarction and paralysis caused by 
597 cerebrovascular diseases (Xiao et al 2016). Scutellarin has a poor oral bioavailability, which is partly 
598 related to the efflux effect of membrane transporters such as MRP2 and BCRP (see Table 4 and 5). In 
599 agreement with Li and co-workers (Li et al 2013, Li et al 2014), Chen et al. have shown that pluronic® 
600 F68, pluronic® F-127, pluronic® P85, and pluronic® P105 increased A-B permeability and decreased B-
601 A permeability of the MRP2 substrate, baicalein, in MDCK MRP2 cells (Chen et al., 2017), (Table 5). 
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602 Chen and co-workers have suggested that these observations were due to MRP2 inhibition (Chen et al., 
603 2017).
604 In contrast, vinblastine transport across MDCKII MRP2 cells was not affected significantly by 0.1 % 
605 (w/v) pluronic® L61 (Evers et al., 2000). Likewise, using a 5-chloromethylfluorescein diacetate 
606 (CMFDA) based accumulation assay in MDCK-MRP2 cells, Bogman et al. (2003) found that the 
607 surfactants TPGS 1000, cremophor® EL, polysorbate 80, pluronic® F68, pluronic® L61, and pluronic® 
608 L81 were unable to inhibit MRP2-mediated methylfluorescein-sulfoglutathione complex (MF-SG) 
609 transport (Bogman et al., 2003). 
610 From Table 4 and 5, it can be noticed that the dose of cremophor® EL needed to inhibit MRP2 or 
611 BCRP in cell cultures and in rats are similar (Xiao et al 2016). Xiao and co-workers have also reported 
612 that cremophor® EL was able to activate the efflux protein MRP3 (Xiao et al 2016), which was found 
613 to be expressed on the basolateral membrane of enterocytes (Kool et al., 1997; Kool et al., 1999). 
614 Therefore, effects of cremophor® EL on scutellarin seems to be related to the effect on multiple efflux 
615 transporters. Thus, activating the efflux transporters, being located in the basolateral membrane in 
616 enterocytes by surfactants could also be a strategy to improve the absorption of substrate drug 
617 substances across intestinal membranes; however, further investigations are needed for this to be a 
618 robust formulation strategy. 
619 An interesting finding reported was that pluronic® F-127 decreased the efflux ratio of scutellarin and 
620 baicalein in Caco-2 cells (Li et al 2013, Li et al 2014) and MDCKII MDRP2 (Chen et al., 2017), 
621 respectively, but had no inhibitory effect on the P-gp substrates rhodamine 123 (Batrakova et al., 
622 2003b), nelfinavir (Shaik et al., 2008), etoposide  (Al-Ali et al., 2018a), and digoxin (Gurjar et al., 
623 2018). Consequently, it may be that there is limited cross inhibitory effects for surfactants inhibiting 
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624 MRP2 towards other efflux membrane transporters and vice versa. The ability of nonionic surfactants 
625 to inhibit MRP2-mediated transport seems to be complex and dependent on the model system 
626 employed to investigate and understand the influence of the surfactant. Therefore, further studies and 
627 specific MRP2 model systems are needed to understand the consequences of MRP2 inhibition by 
628 nonionic surfactants. 
629
630 5. Nonionic surfactants modulate solute carriers in vitro
631 In humans, solute carriers transport endogenous and exogenous (Yu Liang Siqi Li Ligong, 2015), 
632 charged, and uncharged substrates (Koepsell et al., 2007), in and/or out of cells in different tissues, e.g. 
633 intestine, kidney, liver and brain (Giacomini et al., 2010). The SLC family consists of 62 sub-families 
634 (HUGO Gene Nomenclature Committee, 2019). For a protein to be assigned to the SLC family they 
635 need to be responsible for membrane solute transport and to have an amino acid identity of > 20% to 
636 other members of the family (Hediger et al., 2013). Within the SLC family uniporters, symporters and 
637 antiporters are found. The symporters may depend on the driving force of ions such as K+, Na+, H+, or 
638 Cl-, and at a cellular level, they are therefore known as secondary-active transporters (e.g. K+, Na+, or 
639 Cl- -dependent carriers) or tertiary-active transporters (H+-dependent carriers), because the cellular 
640 homeostasis of ions eventually will involve transport by the active NA+/K+-ATPase enzyme. The use of 
641 transporter in this context is a reminiscence of a notion and literature source present prior to the 




644 SLC proteins are diverse in their structures, however, the most common predicted folds of this family 
645 proteins are the Major Facilitator Superfamily (MFS, LacY) and the Leucine transporter (LeuT) that 
646 has folding consisting of 12 and 10 TM helices, respectively. However, some carriers in the SLC 
647 family may possess a lower number of helices, e.g. the glucose uniporter that has a unique fold of 
648 seven TM helices (Colas et al., 2016). For the LacY like fold (Fig. 1d), the protein is oriented in a V-
649 shape conformation opened to the extracellular side of plasma membrane where the substrate is 
650 assumed to bind. The substrate may then move to an intermediate state inside the protein, before it may 
651 release from the inverted V-shape conformation of the SLC to the cytoplasm (Fig. 1d) (Colas et al., 
652 2016). 
653 The oral absorption of a large variety of important nutrient such as amino acids, sugars, peptides, fatty 
654 acids, and vitamins are mediated by carriers, which are important for oral absorption of drug substances 
655 that are structurally similar to the nutrients (Steffansen et al., 2004). Despite the large number of 
656 carriers expressed in the intestine, the effect of nonionic surfactant on these transport systems is largely 
657 uninvestigated. In 2002, Rege and co-workers reported that polysorbate 80 decreased the absorptive 
658 permeability of the prototypic PEPT1 substrate glycyl-sarcosine and cremophor® EL decreased the 
659 transport of the monocarboxylic acid transporter (MCT) substrate benzoic acid in Caco-2 cells (Rege et 
660 al., 2002), (Table 6). Recently, these surfactants have been shown to inhibit other carriers in transfected 
661 cells models. Polysorbate 80 and cremophor® EL inhibited OCT1-3 and PEPT2 in MDCKII OCT1-3 
662 cells and MDCKII PEPT2 cells, respectively. From Table 6, it can be noticed that polysorbate 80 
663 appeared more potent than cremophor® EL with respect to inhibition of OCT1-3 and PEPT2 in cell 
664 cultures (Otter et al., 2017; Soodvilai et al., 2017). In addition, it was reported that cremophor® EL 
665 inhibited OATP1A2 and OATP2B1 in HEK OATP1A2 and HEK OATP2B1 cells, respectively (Engel 
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666 et al., 2012). Furthermore, poloxamer 188 and 407 (Otter et al., 2017), and polysorbate 20 and 60 
667 (Otter et al., 2017; Soodvilai et al., 2017), have shown different abilities to inhibit the organic cation 
668 transporters in cell cultures. In MDCKII OCT1 cells, the estimated IC50 of poloxamer 407 (pluronic® 
669 F-127) was approximately 2600-fold and 900-fold higher than the estimated IC50 of polysorbate 80 and 
670 polysorbate 20, respectively (Otter et al., 2017). 
671 Surfactants inhibiting carriers (Table 6) were also reported to inhibit transporters (Table 2-5, and S1) in 
672 cell cultures as exemplified by the observations that Solutol® HS 15 inhibited OATP1A2, OATP2B1 
673 (Engel et al., 2012), OCT1-3, PEPT2 (Otter et al., 2017), and P-gp (Akhtar et al., 2017; Buckingham et 
674 al., 1995; Coon et al., 1991; Cornaire et al., 2004; Gurjar et al., 2018; Lamprecht and Benoit, 2006); 
675 polysorbate 80 inhibited OCT1-3, PEPT1-2 (Otter et al., 2017; Rege et al., 2002; Soodvilai et al., 
676 2017), P-gp (Al-Ali et al., 2018b; Al-Saraf et al., 2016; Cornaire et al., 2004; Hanke et al., 2010; Kiss 
677 et al., 2014; Lo, 2003; Nerurkar et al., 1996; Nielsen et al., 2016; Shono et al., 2004; Woodcock et al., 
678 1992; Yu et al., 2011), and MRP2 (Hanke et al., 2010); and cremophor® EL inhibited OATP1A2, 
679 OATP2B1 (Engel et al., 2012), OCT1-3, PEPT2 (Otter et al., 2017), MCT (Rege et al., 2002), P-gp 
680 (Al-Ali et al., 2018a; Al-Saraf et al., 2016; Buckingham et al., 1995; Chiu et al., 2003; Nerurkar et al., 
681 1996; Rege et al., 2002; Shono et al., 2004; Woodcock et al., 1990; Woodcock et al., 1992), BCRP 
682 (Sawangrat et al., 2018a; Xiao et al., 2016; Yamagata et al., 2007a), and MRP2 (Hanke et al., 2010; Li 
683 et al., 2013a; Xiao et al., 2016). Cremophor® EL seems to be the surfactant with the widest range of 
684 inhibition of different carriers and transporters. Importantly, impact of surfactant on transporters and 
685 carriers simultaneously may lead to unpredictable drug-transporter interactions. Therefore, further 
686 knowledge about the ability of nonionic surfactants to inhibit carriers under relevant in vivo conditions 
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687 is needed for drug formulators to make enlightened choices on nonionic surfactants as pharmaceutical 
688 excipients.  
689 As generally presented in this review, a broader class of surfactants that are often used as 
690 pharmaceutical excipients, may have effects on drug absorption through interactions with either 
691 transporters, or carriers, or both. While a lot of insights have been generated in vitro, less is available in 
692 vivo from non-clinical trials, and no information is publicly available from human trials systematically 
693 investigating the influence of pharmaceutical excipients on transporters or carriers. Drug prescribers 
694 and pharmacists should therefore be aware that in treatment of patients with polypharmacy 
695 prescriptions of drug compounds that are known substrates to transporters or carriers should be 
696 administered separately from drug products containing nonionic surfactants and co-surfactant polymers 
697 in order to avoid unexpected interactions of drug-excipient at transporters and/or carriers, as this might 
698 lead to unpredicted side effects.
699
700 6. Conclusion
701 From the present review, it is quite evident that pharmaceutical excipients are not just compounds 
702 required for processing drug formulations, but they also possess the ability to alter drug transport across 
703 biological barriers by interacting with transporters and carriers. Pharmaceutical excipients frequently 
704 used in enabling formulations, notably nonionic surfactants, alter the function of carriers and/or 
705 transporters, thereby affecting drug transport. The main body of evidence for this is based on in vitro 
706 experiments using cell culture models or excised tissue, whereas pre-clinical studies available in the 
707 literature are limited. Few studies have investigated if surfactants reduce transporter-mediated transport 
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708 and thereby increase the oral bioavailability; while to the best of our knowledge no in vivo study has 
709 investigated if excipients inhibit carriers in vivo, and hence could decrease oral bioavailability. 
710 Therefore, more pre-clinical studies are needed to investigate if surfactants at concentration likely to be 
711 reached in the intestinal lumen may alter the exposure of substrates of transporters and carriers. It 
712 seems likely that inhibition of transporters by surfactants could be incorporated into a formulation 
713 approach, while a potential inhibition of solute carriers should be avoided as this would decrease oral 
714 absorption. The key points missing are what the scaling between in vitro and in vivo effects is and if 
715 enabling formulations containing surfactants are safe i.e. without toxic effects. Such biopharmaceutical 
716 insight may assist in the active development of formulations where excipients are bioactive 
717 components included for inhibition of intestinal efflux transport. Interestingly, some surfactants, e.g. 
718 cremophor® EL, Solutol® HS 15 and polysorbate 20, have been shown to share inhibiting effects on 
719 several transporters and carriers in vitro. In addition, the concentration of surfactants that inhibit the 
720 efflux transporters P-gp, BCRP, and MRP2 were comparable in cell cultures. Hence, when drug 
721 substances such as doxorubicin and etoposide are substrates for multiple efflux transporters, co-
722 administration of these with surfactants can generate a complex absorption mechanism. 
723 As more and more discovered compounds have limited aqueous solubility, the need for enabling 
724 formulations, that may include surfactants, are increasing. Given that surfactants can have multiple 
725 physico-chemical as well as biopharmaceutical properties, drug formulators may need to bring this 
726 perspective into consideration when defining the formulations of the future. 
727
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1271 Figure 1: Structures of membrane transport proteins in the absence and presence of a substrate. 
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1272 Cartoons illustrate: a) Inward-facing P-glycoprotein (P-gp) (mouse Abcb1, left) and the outward-facing 
1273 P-gp (human ABCB1, right, substrate release), transmembrane domain 1 (TMD1) (1-6 transmembrane 
1274 helices (TMH)), TMD2 (7-12 TMH), extracted with modifications from (Aller et al., 2009; Kim and 
1275 Chen, 2018); b) Two monomers of breast cancer resistance protein (BCRP), BCRP monomer-1 (1-6 
1276 TMH, white) and -2 (1-6 TMH, dark gray), substrate-free state (left) using MsbA from Escherichia coli 
1277 as a template, substrate-bound state (right) using mouse Abcb1 as the template, extracted with 
1278 modifications from (Rosenberg et al., 2010; Rosenberg et al., 2015);  c) Multidrug resistance-
1279 associated protein 2 (MRP2), TM0 (1-5 TMH), TMD1 (6-11 TMH), TMD3 (12-17 TMH), Lasso motif 
1280 (L0), left is when substrate-free state, and right when substrate-bound state, the molecular structure is 
1281 determined using bovine Mrp1 as a template, extracted with modifications from (Dallas et al., 2006; 
1282 Johnson and Chen, 2017); d) Lactose permease of Escherichia coli (LacY) representing a solute carrier 
1283 (SLC) member with 12 TMHs, LacY consists of two segments, each containing two repeat units of 
1284 three TMHs (1-3, 4-6, 7-9 and 10-12) as dark gray, black, white and light gray rods, respectively , 
1285 outward-open conformation (V-shape, substrate-free state,  left) and inward-open conformation 
1286 (inverted V-shape, substrate-released state, right) facing the extracellular and cytoplasmic side of the 
1287 cellular membrane, respectively, extracted with modifications from (Colas et al., 2016; Kumar et al., 
1288 2018; Kumar et al., 2014; Radestock and Forrest, 2011). Nucleotide binding domain (NBD), adenosine 
1289 tri-phosphate (ATP), TMHs are depicted as rods, straight-dashed arrow represents the direction of 
1290 substrate movement, curved arrow represents the direction of helices movement during conformational 





1294 Figure 2: Proposed mechanisms of P-glycoprotein inhibition by nonionic surfactants. 
1295 Cartoon shows: I) Surfactant-P-gp interaction via hydrogen bonding, the hydrophobic moiety of the 
1296 surfactant partitions into the cell membrane, while the hydrogen bond acceptor groups in the 
1297 hydrophilic moiety of the surfactant form hydrogen bonds with the hydrogen bond donor groups in P-
1298 gp, II) Alteration of membrane fluidity and/or (III) depleted intracellular ATP. Transmembrane helices 
1299 are depicted as rods. Nucleotide binding domain (NBD), adenosine tri-phosphate (ATP), adenosine 
1300 diphosphate (ADP), extracellular (Ex.), intracellular (In.), black triangle (P-gp substrate), red circle 
1301 attached to a tail (nonionic surfactant), and black dashed lines (hydrogen bonds). 
1302
1303 Table 1: Expression of selected transporters and carriers along the human intestine and in Caco-2 cells.
1304 Logarithmic 10-step color scale and annotation of expression levels (very low-very high) have 
1305 arbitrarily been defined for overview in the range 0-15 pmol/mg total protein and 0-450 fmol/mg total 
1306 tissued:
1307 To be inserted as a footnote under Table 1: LC-MS/MS-determined protein concentrations (pmol/mg 
1308 total protein) of selected transporters and carriers in Caco-2 cells and segments of the human 
1309 gastrointestinal tract. Protein concentrations from Caco-2 cells were obtained three weeks after seeding. 
1310 Caco-2 cells were from three different sources: American Type Culture Collection (ATCC)a, The 
1311 European Collection of Authenticated Cell Cultures (ECACC)b, and Deutsche Sammlung von 
1312 Mikroorganismen und Zellkulturen (DSMZ)c. The average values are depicted without statistical 
1313 deviation parameters. For (Akazawa et al., 2018), the average were obtained from two reported values 
1314 from two humans, and if one of the two values was below the lower limit of quantification (LLOQ), the 
1315 other value is depicted. Intestinal segments were adapted from (Drozdzik et al., 2014): Duodenum (D), 
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1316 jejunum (J1-2), ileum (I1-2), and colon (C1-4). BLQ = below the LLOQ. Logarithmic 10-step color 
1317 scale and annotation of expression level (very low-very high) have arbitrarily been defined for 
1318 overview in the range 0-15 pmol/mg total protein and 0-450 fmol/mg total tissued:
1319
1320 Table 2: In vitro Iimpact of selected nonionic surfactants and polyethylene glycol (PEG) derivatives on 
1321 P-glycoprotein in vitro.
1322 To be inserted as a footnote under Table 2: Accumulation (accum.), Approximately (approx.), 
1323 Respectively (resp.), Surfactant (surf.), Concentration (conc.), Dependent (dep.), Not specified in the 
1324 study (ns), Apical to basolateral (A-B), Mucosal to serosal (M-S), Permeability (Papp), Any increase or 
1325 decrease described in the table means significant P<0.05, Resistance Modification Index (RMI), Mouse 
1326 embryo fibroblasts transfected with MDR1 (NIH-MDR1-G185), Mouse embryo fibroblasts transfected 
1327 with MDR1 (NIH-MDR1-G185), P-gp overexpressing human melanoma cell line (MDA-MB-
1328 435/LCC6MDR1), P-gp overexpressing human ovarian carcinoma cell line (NCI/ADR-RES), 
1329 Adriamycin-resistant of murine leukaemia P388  cells (P388/ADR), P-gp variant of human epithelial 
1330 cells KB 3-1 (KB 8-5-11 cells), In Vitro Diffusion Chamber Method (In vitro DCM), ATPlite 1step 
1331 Assay kit was from PerkinElmer, P-gp containing membranes of Chinese hamster lung fibroblasts (DC-
1332 3F/ADX cells), MDR cell subline of Chinese hamster ovary cells Aux-B1(CHrC5), Bovine brain 
1333 microvessel endothelial cells (BBMEC), Vinblastine-resistant derivative of Human Caucasian acute 
1334 lymphoblastic leukaemia CCRF-CEM cells (R100 cells), Human lung adenocarcinoma cell line A549 
1335 treated with paclitaxel (A549/Taxol), Porcine kidney epithelial cell line (LLC-PK1-MDR1), LLC-PK1 
1336 stably expressing MDR1 (LLC-MDR1), P-gp overexpressing human oral epidermal carcinoma (KBv), 
1337 For cremophor® EL and Solutol® HS 15, RMI was measured at 10 µg/mL, P-gp overexpressing human 
1338 melanoma cell line (MDA-MB-435/LCC6MDR1), P-gp overexpressing human ovarian carcinoma cell 
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1339 line NCI/ADR-RES, MDR cell subline of human breast carcinoma MCF-7 cells (MCF7/ADR), 
1340 Resistance reversion index (Log (IC50.0/IC50)) was determined as a ratio of IC50 of Doxorubicin in the 
1341 assay buffer and surfactant solution, Vincristine-resistant derivative of K562 (7962 cells), Human lung 
1342 cancer cells (A549), Human P-gp overexpressing membranes obtained from baculovirus-infected insect 
1343 cells (High Five, BTI-TN5B1-4), Clonal isolate derived from the Spodoptera frugiperda cell line IPLB-
1344 Sf-21-AE (Sf9), The disappearance of the drug in perfusate (Plumen) as well as the appearance of the 
1345 drug in mesenteric vein blood (apparent permeability coefficient, Pblood), P-gp overexpressing of 
1346 Chinese hamster ovary AA8 cells (EmtR1). For an overview of the effects of more surfactants on P-gp, 
1347 (see Table S1).
1348
1349 Table 43: Impact of nonionic surfactants on intestinal P-glycoprotein in rats. 
1350 In vivo pre-clinical studies were performed in male a: Sprague-Dawley rats, b: Wistar albino rats. 
1351 Synonyms of surfactants are available in Table 2.
1352
1353
1354 Table 34: In vitro and in vivo Iimpact of nonionic surfactants on breast cancer resistance protein, 
1355 BCRP, in vitro.  
1356 To be inserted as a footnote under Table 4: Concentration (conc.), Approximately (approx.), 
1357 Respectively (resp.), Plasma membrane vesicle of cells containing human ABCG2 (Membrane vesicles 
1358 BCRP), Clonal isolate derived from the Spodoptera frugiperda cell line IPLB-Sf-21-AE (Sf9 insect 
1359 cells), In Vitro Diffusion Chamber Method (In vitro DCM), Serosal to mucosal (S-M), In situ closed-
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1360 loop method (In situ CLM), Wild type (WT), Sprague-Dawley (SD), Synonyms of surfactants are 
1361 available in Table 2. 
1362
1363 Table 4: Impact of nonionic surfactants on intestinal P-glycoprotein in rats. 
1364 In vivo pre-clinical studies were performed in male a: Sprague-Dawley rats, b: Wistar albino rats. 
1365 Synonyms of surfactants are available in Table 2.
1366
1367 Table 5: In vitro and in vivo Iimpact of nonionic surfactants and co-surfactants on multidrug 
1368 resistance-associated protein 2, MRP2, in vitro. 
1369 To be inserted as a footnote under Table 5: Concentration (Conc.), Respectively (resp.), Membrane 
1370 vesicles prepared from Spodoptera frugiperda (Sf9) insect cells over-expressing human MRP2 
1371 (Membrane vesicles of Sf9 MRP2), ATP measurements were performed using ATP 
1372 luciferin/Luciferase assay, Wild type  (WT), Synonyms of surfactants are available in Table 2 and 3.
1373
1374 Table 6: Nonionic surfactants inhibited solute carriers (SLCs) in vitro. 
1375
1376
1377 To be inserted as a footnote under Table 6: IC50 were estimated from upatke transport assay. For Regev 
1378 et al. 2002, imact of surfactant on bi-directional transport assay was shown. 1-methyl-4-
1379 phenylpyridinium acetate (MPP+), Monocarboxylic acid transporter (MCT, SLC16A1), Organic cation 
1380 transporter 1 (OCT1, SLC22A1), (OCT2, SLC22A2), (OCT3, SLC22A3), Peptide transporter 1 
1381 (PEPT1, SLC15A1), (PEPT2, SLC15A2), Organic anion transporting polypeptide 1A2 (OATP1A2, 
1382 SLC21A3), (OATP2B1, SLC21A9). Human embryonic kidney cells stably transfected with OATP1A2 
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1383 (HEK OATP1A2), or with OATP2B1 (HEK OATP2B1), Chinese hamster ovary cells stably 
1384 transfected with rbOCT1(CHO-K1 rbOCT1), Madin-Darby canine kidney cells stably transfected with 
1385 OCT1-3 (MDCKII OCT1-3), or with PEP2 (MDCKII PEPT2). Synonyms of surfactants available in 
1386 Table 2 and 5.
1387
1388 Table S1: In vitro Iimpact of nonionic surfactants and polyethylene glycol (PEG) derivatives on P-
1389 glycoprotein in vitro. 
1390 Accumulation (accum.), Approximately (approx.), Respectively (resp.), Surfactant (surf.), 
1391 Concentration (conc.), Dependent (dep.), Not specified in the study (ns), Apical to basolateral (A-B), 
1392 Mucosal to serosal (M-S), Permeability (Papp), Any increase or decrease described in the table means 
1393 significant P<0.05, Resistance Modification Index (RMI), Mouse embryo fibroblasts transfected with 
1394 MDR1 (NIH-MDR1-G185), Mouse embryo fibroblasts transfected with MDR1 (NIH-MDR1-G185), 
1395 P-gp overexpressing human melanoma cell line (MDA-MB-435/LCC6MDR1), P-gp overexpressing 
1396 human ovarian carcinoma cell line (NCI/ADR-RES), Adriamycin-resistant of murine leukemia P388  
1397 cells (P388/ADR), P-gp variant of human epithelial cells KB 3-1 (KB 8-5-11 cells), In Vitro Diffusion 
1398 Chamber Method (In vitro DCM), ATPlite 1step Assay kit was from PerkinElmer, P-gp containing 
1399 membranes of Chinese hamster lung fibroblasts (DC-3F/ADX cells), Concentration of half-maximum 
1400 activation (K1), Concentration of half-maximum inhibition (K2), MDR cell subline of Chinese hamster 
1401 ovary cells Aux-B1(CHrC5), Bovine brain microvessel endothelial cells (BBMEC), Vinblastine-
1402 resistant derivative of Human Caucasian acute lymphoblastic leukemia CCRF-CEM cells (R100 cells), 
1403 Human lung adenocarcinoma cell line A549 treated with paclitaxel (A549/Taxol), Porcine kidney 
1404 epithelial cell line (LLC-PK1-MDR1), LLC-PK1 stably expressing MDR1 (LLC-MDR1), P-gp 
1405 overexpressing human oral epidermal carcinoma (KBv), For cremophor® EL and Solutol® HS 15, RMI 
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1406 was measured at 10 µg/mL, P-gp overexpressing human melanoma cell line (MDA-MB-
1407 435/LCC6MDR1), P-gp overexpressing human ovarian carcinoma cell line NCI/ADR-RES, MDR cell 
1408 subline of human breast carcinoma MCF-7 cells (MCF7/ADR), Resistance reversion index (Log 
1409 (IC50.0/IC50)) was determined as a ratio of IC50 of Doxorubicin in the assay buffer and surfactant 
1410 solution, Vincristine-resistant derivative of K562 (7962 cells), Human lung cancer cells (A549), 
1411 Human P-gp overexpressing membranes obtained from baculovirus-infected insect cells (High Five, 
1412 BTI-TN5B1-4), Clonal isolate derived from the Spodoptera frugiperda cell line IPLB-Sf-21-AE (Sf9), 
1413 The disappearance of the drug in perfusate (Plumen) as well as the appearance of the drug in mesenteric 
1414 vein blood (apparent permeability coefficient, Pblood), P-gp overexpressing of Chinese hamster ovary 
1415 AA8 cells (EmtR1). 
1416 Table 1: Expression of selected transporters and carriers along the human intestine and in Caco-2 cells.
1417 LC-MS/MS-determined protein concentrations (pmol/mg total protein) of selected transporters and 
1418 carriers in Caco-2 cells and segments of the human gastrointestinal tract. Protein concentrations from 
1419 Caco-2 cells were obtained three weeks after seeding. Caco-2 cells were from three different sources: 
1420 American Type Culture Collection (ATCC)a, The European Collection of Authenticated Cell Cultures 
1421 (ECACC)b, and Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ)c. The average 
1422 values are depicted without statistical deviation parameters. For (Akazawa et al., 2018), the average 
1423 were obtained from two reported values from two humans, and if one of the two values was below the 
1424 lower limit of quantification (LLOQ), the other value is depicted. Intestinal segments were adapted 
1425 from (Drozdzik et al., 2014): Duodenum (D), jejunum (J1-2), ileum (I1-2), and colon (C1-4). BLQ = 
1426 below the LLOQ. Logarithmic 10-step color scale and annotation of expression level (very low-very 
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1427 high) have arbitrarily been defined for overview in the range 0-15 pmol/mg total protein and 0-450 
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1447 Table 2: In vitro Iimpact of selected nonionic surfactants and polyethylene glycol (PEG) derivatives on 
1448 P-glycoprotein in vitro.
1449 Accumulation (accum.), Approximately (approx.), Respectively (resp.), Surfactant (surf.), 
1450 Concentration (conc.), Dependent (dep.), Not specified in the study (ns), Apical to basolateral (A-B), 
1451 Mucosal to serosal (M-S), Permeability (Papp), Any increase or decrease described in the table means 
1452 significant P<0.05, Resistance Modification Index (RMI), Mouse embryo fibroblasts transfected with 
1453 MDR1 (NIH-MDR1-G185), Mouse embryo fibroblasts transfected with MDR1 (NIH-MDR1-G185), 
1454 P-gp overexpressing human melanoma cell line (MDA-MB-435/LCC6MDR1), P-gp overexpressing 
1455 human ovarian carcinoma cell line (NCI/ADR-RES), Adriamycin-resistant of murine leukaemia P388  
1456 cells (P388/ADR), P-gp variant of human epithelial cells KB 3-1 (KB 8-5-11 cells), In Vitro Diffusion 
1457 Chamber Method (In vitro DCM), ATPlite 1step Assay kit was from PerkinElmer, P-gp containing 
1458 membranes of Chinese hamster lung fibroblasts (DC-3F/ADX cells), MDR cell subline of Chinese 
1459 hamster ovary cells Aux-B1(CHrC5), Bovine brain microvessel endothelial cells (BBMEC), 
1460 Vinblastine-resistant derivative of Human Caucasian acute lymphoblastic leukaemia CCRF-CEM cells 
1461 (R100 cells), Human lung adenocarcinoma cell line A549 treated with paclitaxel (A549/Taxol), Porcine 
1462 kidney epithelial cell line (LLC-PK1-MDR1), LLC-PK1 stably expressing MDR1 (LLC-MDR1), P-gp 
1463 overexpressing human oral epidermal carcinoma (KBv), For cremophor® EL and Solutol® HS 15, RMI 
1464 was measured at 10 µg/mL, P-gp overexpressing human melanoma cell line (MDA-MB-
1465 435/LCC6MDR1), P-gp overexpressing human ovarian carcinoma cell line NCI/ADR-RES, MDR cell 
1466 subline of human breast carcinoma MCF-7 cells (MCF7/ADR), Resistance reversion index (Log 
1467 (IC50.0/IC50)) was determined as a ratio of IC50 of Doxorubicin in the assay buffer and surfactant 
1468 solution, Vincristine-resistant derivative of K562 (7962 cells), Human lung cancer cells (A549), 
1469 Human P-gp overexpressing membranes obtained from baculovirus-infected insect cells (High Five, 
1470 BTI-TN5B1-4), Clonal isolate derived from the Spodoptera frugiperda cell line IPLB-Sf-21-AE (Sf9), 
1471 The disappearance of the drug in perfusate (Plumen) as well as the appearance of the drug in mesenteric 
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1472 vein blood (apparent permeability coefficient, Pblood), P-gp overexpressing of Chinese hamster ovary 







Conc. Substrate Cell line/Tissue Assay Impact Reference
(1:1000) Daunorubicin R100 cells Uptake transport Increased intracellular accum. (Woodcock et al., 
1990)
(1:1000) Daunorubicin 7962 cells Uptake transport Increased intracellular accum. (Woodcock et al., 
1990)














Increased A-B and decreased B-A 
Papp.
(Nerurkar et al., 
1996)
100 µg/mL Rh 123 KB 8-5-11 cells Uptake transport Enhanced the fluorescence of Rh 
123 by 3-fold. 
(Buckingham et al., 
1995)
3-20 µg/mL Doxorubicin KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI =1.5 ± 0.0
(Buckingham et al., 
1995)
3-20 µg/mL Vinblastine KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI =1.1 ± 0.1
(Buckingham et al., 
1995)
3-20 µg/mL Colchicine KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI =1.3 ± 0.1
(Buckingham et al., 
1995)
3-20 µg/mL Etoposide KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI =1.2 ± 0.3
(Buckingham et al., 
1995)
3-20 µg/mL, Actinomycin 
D 
KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI =1 ± 0.2
(Buckingham et al., 
1995)




Increased A-B and decreased B-A 
Papp in a conc. dependent manner. 
(Rege et al., 2002)






Decreased B-A Papp. (Chiu et al., 2003)
0.005-0.5% 
(w/v)





Increased S-M and decreased M-S 
Papp.
(Shono et al., 2004)




Increased A-B Papp. (Al-Saraf et al., 
2016)




Increased A-B and decreased B-A 
Papp.
(Al-Ali et al., 2018a) 
1% SMEDDS 
containing 










Increased intestinal Papp. iIncreased 
PBlood and PLumen.




oil, PEG-35 castor 
oil, Polyoxyl 35 
hydrogenated 
castor oil
0.3-1000 µM Digoxin  MDCKII MDR1 Uptake transport Increased intracellular accum. in a 
conc. dependent manner. IC50 = 12 
µM
(Gurjar et al., 2018)
PEG 300,
Polyethylene glycol 




Increased A-B and decreased B-A 
Papp in a conc. dependent manner.
(Hugger et al., 2002)
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Increased A-B and decreased B-A 
Papp in a conc. dependent manner.
(Hugger et al., 2002)




Decreased ranitidine ER. (Ashiru-Oredope et 
al., 2011)
300
300 µM PREDEASY 
ATPase Kit
Increased P-gp ATPase activity. (Ashiru-Oredope et 
al., 2011)
1, 5 and 20% 
(w/v)





Decreased S-M flux by 47, 57 and 
64%, resp., compared to control.
(Johnson et al., 
2002) 





Decreased S-M Papp in a conc. dep. 
manner. 
(Shen et al., 2006)




Decreased ER. (Ashiru-Oredope et 
al., 2011)
0.5 and 1% 
(v/v)








300 µM PREDEASY 
ATPase Kit
Increased P-gp ATPase activity. (Ashiru-Oredope et 
al., 2011)
1 and 2% 
(w/v)
Rh 123 Caco-2 cells Uptake transport Enhanced Rh 123 intracellular 
accum.
(Hodaei et al., 2015)
PEG 400
1 and 2% 
(w/v)
Caco-2 cells Western blotting Decreased P-gp expression. (Hodaei et al., 2015)
Doxorubicin KBv Log (IC50.0/IC50) = 0.7 (Batrakova et al., 
1999)
Doxorubicin MCF7/ADR Log (IC50.0/IC50) = 0.8 (Batrakova et al., 
1999)
Doxorubicin CHrC5 Log (IC50.0/IC50) = 2 (Batrakova et al., 
1999)
Log M = -5 Rh 123 KBv Uptake transport Enhanced Rh 123 accum. by approx. 
6.5-fold.
(Batrakova et al., 
1999)
0.001-1% Rh 123 LLC-PK1-MDR1 Uptake transport Increased Rh 123 accum. (Batrakova et al., 
2001)
0.001-1% Digoxin LLC-PK1-MDR1 Uptake transport Increased digoxin accum. (Batrakova et al., 
2001)
0.01-1% Digoxin BBMEC A-B transport Increased A-B transport. (Batrakova et al., 
2001)
0.01% Digoxin BBMEC A-B transport Increased A-B and decreased 
transport.
(Batrakova et al., 
2001)
0.01 and 0.1% 
(w/v)





Decreased S-M flux. (Johnson et al., 
2002) 
Pluronic® P85
0.01% (w/v) Rh 123 BBMEC Uptake transport Enhanced Rh 123 accum. by approx. 
2-fold. Depleted intracellular ATP 
content. Decreased the P-gp ATPase 





0.01% (w/v) Rh 123 BBMEC ATP luciferin/
luciferase
Depleted intracellular ATP content. (Batrakova et al., 
2003)
0.01% (w/v) Rh 123 KBv Pgp ATPase 
activity
Decreased the P-gp ATPase activity. (Batrakova et al., 
2003)
0.1% w/v P-gp membranes 
from Gentest Co. 
P-gp ATPase 
Assay
Decreased Vmax and increased Km 
significantly.
(Batrakova et al., 
2004)
0.01 and  
0.1% w/v
Vincristine P-gp membranes 
from Gentest Co.
 P-gp ATPase 
Assay
Decreased Vmax and increased Km 
significantly.
(Batrakova et al., 
2004)





Increased M-S Papp by1.9-fold. (Föger et al., 2006)





Abolished P-gp ATPase activity 
completely.
(Shaik et al., 2008)





Inhibited verapamil-stimulated P-gp 
ATPase activity.
(Shaik et al., 2008)





Abolished the nelfinavir stimulated 
P-gp ATPase activity.
(Shaik et al., 2008)
0.01% w/w Nelfinavir MDCKII MDR1 Uptake transport Enhanced nelfinavir accum. (Shaik et al., 2008)
0.01% w/w Saquinavir MDCKII MDR1 Uptake transport Increased saquinavir accum. by 2-
fold.
(Shaik et al., 2008)
0.01% w/w Saquinavir LLC-PK1-MDR1 Uptake transport Increased saquinavir accum. by 5-
fold.
(Shaik et al., 2008)
0-600 ng/mL Membrane 





Reduced P-gp ATPase activity in a 
conc. dep. manner. 
(Regev et al., 1999)




Decreased Flip-Flop Life-Time of 
doxorubicin in a conc. dep. manner.
(Regev et al., 1999)
30-100 ng/mL Clacein-AM EmtR1 cells Calcein-AM 
efflux
Enhanced calcein-AM uptake in a 
conc. dep. manner.
(Regev et al., 1999)
0.5% (w/v) Digoxin Rat everted gut 
sac model 
Uptake transport Enhanced digoxin accum. (Cornaire et al., 
2004)




Increased A-B and decreased B-A 
Papp.
(Lo, 2003)
20-200 µM Epirubicin Caco-2 cells Uptake transport Enhanced fluorescent epirubicin 
accum. in a conc. dep. manner.
(Lo, 2003)
200 µM Epirubicin Everted sacs of 
rat´s jejunum or 
ileum


















Increased A-B and decreased B-A 
Papp.
(Nielsen et al., 2016)




Increased A-B and decreased B-A 
Papp in a conc. dep. manner. 
(Nielsen et al., 2016)




Increased A-B and decreased B-A 
Papp in a conc. dep. manner. 
(Nielsen et al., 2016)




Increased A-B Papp. (Al-Ali et al., 2018a)




Decreased B-A Papp. (Al-Ali et al., 2018a)




Increased A-B and decreased B-A 
Papp.
(Al-Ali et al., 2018a)
Calcein-AM MDCKII MDR1 Calcein-AM 
efflux
Increased calcein fluorescence in a 
conc. dep. manner. IC50 = 11 µM.
(Al-Ali et al., 
2018b)
200 µM Digoxin MDCKII MDR1 Bi-directional 
transport
Increased A-B and decreased B-A 
Papp. 
Increased intracellular accum. of 
digoxin from the apical side.
(Al-Ali et al., 
2018b) 
0.3-1000 µM Digoxin  MDCKII MDR1 Uptake transport Increased intracellular accum. in a 
conc. dependent manner. IC50 = 74 
µM.
(Gurjar et al., 2018)
200 µM Epirubicin Everted sacs of 
jejunum or ileum 
of rats
M-S transport Increased M-S Papp (Lo, 2003)
20-200 µM Epirubicin Caco-2 cells Uptake transport Enhanced intracellular accum. of 
fluorescent epirubicin in a conc. dep. 
manner. 
(Lo, 2003)




Increased A-B and decreased B-A 
Papp. 
(Lo, 2003)
0.5 w/v Digoxin Rat everted gut 
sac model 
Uptake transport Enhanced digoxin uptake. (Cornaire et al., 
2004)




Increased A-B and decreased B-A 
Papp in a conc. dep. manner. 
(Rege et al., 2002)
Rh 123 Caco-2 Uptake transport Increased Rh 123 accum. (Kiss et al., 2014) 




Increased A-B and decreased B-A 
Papp.
(Kiss et al., 2014)
Calcein-AM Caco-2 cells Uptake transport Increased calcein accum. (Kiss et al., 2014) 
(1:10000) Daunorubicin R100 cells Uptake transport Increased intracellular daunorubicin 
accum.










Increased A-B and decreased B-A 
Papp.




















Inhibition of verapamil-induced P-gp 
ATPase activity.




Clacein-AM MDCKII MDR1 Calcein-AM 
efflux 
Enhanced calcein fluorescence by 
approx. 2-fold. 







Increased A-B Papp and decreased B-
A Papp.







Decreased B-A Papp. (Yu et al., 2011)




Increased A-B Papp. (Al-Saraf et al., 
2016)




Increased A-B and decreased B-A 
flux.
(Nielsen et al., 2016)




Increased A-B and decreased B-A 
Papp.
(Al-Ali et al., 2018a)
1% SMEDDS 
containing 










Increased intestinal Papp. Increased 
PBlood and PLumen.
(Zhao et al., 2013)
Calcein-AM MDCKII MDR1 Calcein-AM 
efflux
Increased calcein fluorescence in a 
conc. dep. manner. IC50= 69 µM
(Al-Ali et al., 
2018b)
200 µM Digoxin MDCKII MDR1 Bi-directional 
transport
Decreased B-A Papp.
Increased intracellular accum. of 
digoxin from the apical side.
(Al-Ali et al., 
2018b) 
0.3-100 µM Digoxin  MDCKII MDR1 Uptake transport Increased intracellular accum. in a 
conc. dep. manner. IC50 = 45 µM
(Gurjar et al., 2018)
0.05-0.5 % 
(w/v)
Digoxin Rat everted gut 
sac model 
Uptake transport Enhanced digoxin accum. (Cornaire et al., 
2004)
(1:10000) Daunorubicin R100 cells Uptake transport Increased intracellular daunorubicin. (Woodcock et al., 
1992)
Etoposide C6 glioma cells MTT Decreased IC50 by 10-fold. (Lamprecht and 
Benoit, 2006)
Etoposide F98 glioma cells MTT Decreased IC50 by 3-fold. (Lamprecht and 
Benoit, 2006)











Decreased ATPase activity. (Lamprecht and 
Benoit, 2006)
5-100 µg/mL Rh 123 KB 8-5-11 cells Uptake transport Enhanced fluorescence of Rh 123 in 
a conc. dep. manner. 
(Buckingham et al., 
1995)
Solutol® HS 15, 










3-20 µg/mL Doxorubicin KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI = 6 ± 3.2




3-20 µg/mL Vinblastine KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI = 2 ± 1
(Buckingham et al., 
1995)
3-20 µg/mL Colchicine KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI = 4.2 ± 0.7
(Buckingham et al., 
1995)
3-20 µg/mL Etoposide KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI = 2.7 ± 0.7
(Buckingham et al., 
1995)
3-20 µg/mL Actinomycin 
D 
KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI = 2.3 ± 0.9
(Buckingham et al., 
1995)
3-20 µg/mL Paclitaxel KB 8-5-11 cells MTT Decreased IC50 in a conc. dep. 
manner. RMI=10 ± 1.2
(Buckingham et al., 
1995)
0.1 – 100 µM Colchicine KB 8-5-11 cells Colorimetric 
(Crystal violet)
Decreased IC50 in a conc. dep. 
manner. RMI = 34.5 ± 2.5
(Coon et al., 1991)
0.1 – 100 µM Vinblastine KB 8-5-11 cells Colorimetric 
(Crystal violet)
Decreased IC50 in a conc. dep. 
manner. RMI = 27.7 ± 2.3
(Coon et al., 1991)
0.1 – 100 µM Doxorubicin KB 8-5-11 cells  Colorimetric 
(Crystal violet)
Decreased IC50 in a conc. dep. 
manner. RMI = 41.7 ± 3 
(Coon et al., 1991)
70 µM Rh 123 KB 8-5-11 cells Uptake transport Increased accum. by 50-fold. (Coon et al., 1991)
0.1-1 % (w/v) Etoposide Everted sacs of 
ileum of rats
M-S and S-M 
transport 
Increased A-B Papp (Akhtar et al., 2017)
0.3-1000 µM Digoxin  MDCKII MDR1 Uptake transport Increased intracellular accum. in a 
conc. dep. manner. IC50 = 180 µM
(Gurjar et al., 2018)
0.05-0.5% w/v Digoxin Rat everted gut 
sac model 
Uptake transport Enhanced digoxin accum. (Cornaire et al., 
2004)
0.05 and 0.5 
w/v
Celiprolol Rat everted gut 
sac model











Decreased B-A Papp in a conc. dep. 
manner. Increased A-B Papp.
(Varma and 
Panchagnula, 2005)








Increased intestinal Papp. (Varma and 
Panchagnula, 2005)
Verapamil P-gp membranes 
from Sf9 
ATPase Inhibited substrate induced ATPase 
activity. IC50 (µM) = 3.18 ± 1.97
(Collnot et al., 2007)
Quinidine P-gp membranes 
from Sf9 
ATPase Inhibited substrate induced ATPase 
activity. IC50 (µM) = 0.82 ± 0.47
(Collnot et al., 2007)
Progesterone P-gp membranes 
from Sf9 
ATPase Inhibited substrate induced ATPase 
activity. IC50 (µM) = 3.25 ± 1.29
(Collnot et al., 2007)
 Nicardipine P-gp membranes 
from Sf9 
ATPase Inhibited substrate induced ATPase 
activity. IC50 (µM) = 0.40 ± 0.17
(Collnot et al., 2007)






















1478 Table 43: Impact of nonionic surfactants on intestinal P-glycoprotein in rats. 
1479 In vivo pre-clinical studies were performed in male a: Sprague-Dawley rats, b: Wistar albino rats. 
1480 Synonyms of surfactants are available in Table 2.
Calcein-AM NCI/ADR-RES Calcein-AM 
efflux 
Dose-dependent increase in calcein 
fluorescence.





Dose-dependent increase in calcein 
fluorescence.
(Dong et al., 2009)
0.005% 
(w/v)












Increased A-B and decreased B-A 
Papp.
(Bogman et al., 
2005)






Decreased B-A Papp of cyclosporin 
A. 
(Chiu et al., 2003)
0.001-0.05% 
(w/v)
Calcein-AM MDCKII MDR1 Calcein-AM 
efflux 
Enhanced calcein fluorescence by 
approx. 2-fold.
(Hanke et al., 2010)
0.3-1000 µM Digoxin  MDCKII MDR1 Uptake transport Increased intracellular accum. in a 
conc. dep. manner. IC50 = 12 µM
(Gurjar et al., 2018)
Surfactant Dose of surfactant Substrate 
(Dose)
Impact Reference 




Increased AUC, Cmax, and F by 1.7-, 1.3-, and 
1.7-fold, respectively.
(Zhao et al., 2013)
Cremophor® RH 40 
Kolliphor® RH 40, 
PEG-40 castor oil  




Increased AUC, Cmax, and F by 1.4-, 1.3-, and 
1.4-fold, respectively.
(Zhao et al., 2013)
240 mg/kg Rifampicin b Increased AUC by 1.5-fold,   prolonged t½ by 
25%, and  decreased CL to 60%
(Ma et al., 2011)
1% (w/v) Etoposide b  
(4.5 mg/kg)
Increased AUC, Cmax, and F by 1.8-, 4.7-, and 
1.8-fold, respectively.
(Akhtar et al., 2017)
5% (w/v) Etoposide b
(4.5 mg/kg)
Increased AUC, Cmax, and F by 3-, 7-, and 3-
fold, respectively.







10% (w/v) Etoposide b
(4.5 mg/kg) 
Increased AUC, Cmax, and F by 1.6-, 6-, and 1.6-
fold, respectively.
(Akhtar et al., 2017)
Myrj 52,  
Polyoxyethylene (40) 
8.5 mg/table Rh 123 a 
(1.5 mg/tablet)






1484 Table 34: In vitro and in vivo iImpact of nonionic surfactants on breast cancer resistance protein, 
1485 BCRP, in vitro and in vivo.  
1486 Concentration (conc.), Approximately (approx.), Respectively (resp.), Plasma membrane vesicle of 
1487 cells containing human ABCG2 (Membrane vesicles BCRP), Clonal isolate derived from the 
1488 Spodoptera frugiperda cell line IPLB-Sf-21-AE (Sf9 insect cells), In Vitro Diffusion Chamber Method 
stearate
Pluronic® F68 240 mg/kg Rifampicin b  Increased AUC by 1.5-fold, prolonged t½ by 
38%, and decreased CL to 60%.
(Ma et al., 2011)
Pluronic® P85 8.5 mg/table Rh123 a  
(1.5 mg/tablet)
Increased AUC by 1.6-fold. (Föger et al., 2006)
10-25% (v/v) Digoxin a
(0.2 mg/kg)
Increased AUC by 1.4-fold, increased Cmax by 
1.4-1.8-fold, increased ke by 1.4-1.6-fold, and 
increased F by approx.1.5-fold.
(Nielsen et al., 2016)Polysorbate 20
5 and 25% (v/v) Etoposide a
(20 mg/kg)
Increased AUC by 1.8-fold, increased Cmax by 
1.5-2.1-fold, CL decreased by half, and 
increased F by 1.7-fold.
(Al-Ali et al., 2018)
1 and 10%(v/v) Digoxin a
(0.2 mg/kg)
Increased AUC by 1.3-1.6-fold and increased 
Cmax by 2.5-fold
(Zhang et al., 2003)
10% Rifampicin b
(30 mg/kg)
Increased AUC by 1.7-fold and decreased t½ to 
36%.








Increased Cmax by 3.5-fold, increased F and 
AUC by 2.5-fold.
(Zhao et al., 2013)
Softigen® 767, 
PEG 400 caprylic / 
capric glycerides
1 mg/kg Digoxin a
(0.25 mg/kg)
Increased AUC by 1.4-fold and decreased tmax 
by 4.5-fold.
(Cornaire et al., 2004)
Solutol® HS 15 10% Colchicine
(5mg/kg)
Increased AUC by 4-fold. (Bittner et al., 2002)
10% Colchicine
(5mg/kg)
Increased AUC by 2-fold. (Bittner et al., 2002)TPGS 1000 
 50 mg/kg Paclitaxel a
(25 mg/kg)






1489 (In vitro DCM), In situ closed-loop method (In situ CLM), Wild type (WT), Sprague-Dawley (SD), 















Nonionic surfactants Conc. Substrate Cells/Tissue/
Animal







Reduced Pgp ATPase 
activity. K2 = 4.6 103 µM
(Xu et al., 2015)
0.05% and 
0.075%
Sulfasalazine Rat intestinal 
membrane
In vitro DCM Decreased S-M B-A 
transport. 
(Sawangrat et al., 
2018a)
0.05 % Sulfasalazine WT male Wistar 
rat
In situ CLM Increased AUC and Cmax by 
1.45 and 1.4- folds, resp.




Polyoxyethylene (9) lauryl 
ether, C12EO9
0.1 % Sulfasalazine WT male Wistar 
rat
In situ CLM Increased AUC and Cmax by 
2.2 and 2.1-folds, resp. 
(Sawangrat et al., 
2018a)
Brij® 30, 
Polyoxyethylene (4) lauryl 
ether, C12EO4, Brij® L4
50 and 100 
µM
Mitoxantrone MDCKII BCRP Uptake transport Increased the uptake by 
approx. 1.7-fold.






Sulfasalazine Rat intestinal 
membrane
In vitro DCM Decreased S-M B-A 
transport. 
(Sawangrat et al., 
2018a)
Brij® 97, 
Brij® O10, Polyoxyethylene 
(10) oleyl ether 0.1 % Sulfasalazine WT male Wistar 
rat
In situ CLM Increased AUC and Cmax by 
1.8 and 2.3-fold, resp. 
(Sawangrat et al., 
2018a)
50 µM Mitoxantrone MDCKII BCRP Uptake transport Increased the uptake by 
approx. 1.4-fold.
(Yamagata et al., 
2007a)
6.25-100 nM Scutellarin Membrane 
vesicles of Sf9 
BCRP
Uptake transport Increased the uptake in a 
conc. dependent manner.
(Xiao et al., 
2016)
1 and 5 
µg/mL
Scutellarin MDCKII BCRP Bi-directional 
transport
Increased A-B and 
decreased B-A Papp.
(Xiao et al., 
2016)
5 µg/mL Scutellarin WT Male SD 
rats
 Increased AUC and Cmax2 
by 1.6 and 1.9-folds, resp.








Increased A-B and/or 
decreased B-A Papp.
(Sawangrat et al., 
2018b)
Cremophor® EL 
0.05 % (w/v) Topotecan WT male Wistar 
rat








Reduced P-gp ATPase 
activity. K2 = 1.51 104 µM
(Xu et al., 2015)
0.075% Sulfasalazine Rat intestinal 
membrane
In vitro DCM Decreased S-M B-A 
transport. 









Increased A-B Papp. (Sawangrat et al., 
2018b)
Pluronic® F68 0.025 and 
0.05% (w/v)




Decreased B-A Papp. (Sawangrat et al., 
2018b)
20 µM Mitoxantrone MDCKII BCRP Uptake transport Increased the uptake by 
approx. 1.8-fold.
(Yamagata et al., 
2007a)




WT mice Increased the AUC by 2-
folds.
(Yamagata et al., 
2007b)
20 µM Topotecan Everted
sacs from WT 
mice ileum 
Transport Increased the intestinal 
absorption rate of topotecan.
(Yamagata et al., 
2007b)
Pluronic® P85 
20 µM Mitoxantrone MDCKII BCRP Uptake transport Increased the uptake.   (Yamagata et al., 
2009)







Reduced Pgp ATPase 
activity. K2 = 6.93 µM
(Xu et al., 2015)
100 and 250 
µM
Mitoxantrone MDCKII BCRP Uptake transport Increased the uptake by 
approx. 1.6-fold.
(Yamagata et al., 
2007a) 
Polysorbate 20







1509 Table 5: In vitro and in vivo impact of nonionic surfactants and co-surfactants on multidrug resistance-
1510 associated protein 2 MRP2. 
1511 Concentration (Conc.), Respectively (resp.), Membrane vesicles prepared from Spodoptera frugiperda 
1512 (Sf9) insect cells over-expressing human MRP2 (Membrane vesicles of Sf9 MRP2), ATP 
1513 measurements were performed using ATP luciferin/Luciferase assay, Wild type  (WT), Synonyms of 
1514 surfactants are available in Table 2 and 3.
1515
1516
(Oral) (Oral) fold. 2007b)
250 µM Topotecan Everted
sacs from WT 
mice ileum
Transport Increased the intestinal 
absorption rate.
(Yamagata et al., 
2007b)




Sulfasalazine Rat intestinal 
membrane 
In vitro DCM Decreased S-M B-A 
transport. 








Increased A-B and 
decreased B-A Papp.
(Sawangrat et al., 
2018b)
0.05 % (w/v) Topotecan WT male Wistar 
rat




100 µM Mitoxantrone MDCKII BCRP Uptake transport Increased the uptake by 
approx. 1.4-fold.
(Yamagata et al., 
2007a) 
Surfactant Conc. Substrate Cells or animal Assay Impact of surfactant Reference
0.005-0.05% 
(v/v)
Calcein-AM MDCKII MRP2 Bi-directional 
transport 
Decreased B-A Papp. (Hanke et al., 2010)Cremophor® EL
100 µg/mL Scutellarin Membrane vesicles of 
Sf9 MRP2 
Uptake transport Increased the uptake. (Li et al., 2013)
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Decrease ER. (Li et al., 2013)
0.1-100 
µg/mL




Decreased ER in a conc. 
dependent manner.
(Li et al., 2014)
0.1-100 
µg/mL
Scutellarin Membrane vesicles of 
Sf9 MRP2 
Uptake transport Increased the uptake in a 
conc. dependent manner.
(Li et al., 2014)
6.25-100 nM Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake in a 
conc. dependent manner.
(Xiao et al., 2016)
1 and 5 µg/mL Scutellarin MDCKII MRP2 Bi-directional 
transport
Decreased B-A Papp. (Xiao et al., 2016)
5 µg/mL Scutellarin WT Male Sprague-
Dawley rats
 Increased AUC and Cmax2 by 
1.6 and 1.9-folds, resp.
(Xiao et al., 2016)
Cremophor® EL + 
Pluronic® F-127
100 μg/ml + 
100 μg/ml
Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake. (Li et al., 2014)
Cremophor® EL + 
PEG 2000 
100 μg/ml + 
100 μg/ml
Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake. (Li et al., 2014)
0.02-0.04%
(v/v)
Calcein-AM MDCKII MRP2 Bidirectional 
transport
Decreased B-A Papp. (Hanke et al., 2010)
100 µg/mL Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake. (Li et al., 2013)




Decreased ER. (Li et al., 2013)
0.1-100 
µg/mL




Decreased ER in a conc. 
dependent manner.
(Li et al., 2014)
Cremophor® RH 40 
0.1- 100 
µg/mL
Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake in a 
conc. dependent manner.
(Li et al., 2014)
Labrasol® 0.1-100 
µg/mL




Decreased ER. (Li et al., 2014)





Increased the uptake. (Li et al., 2013)




Decreased ER. (Li et al., 2013)
0.1-100 
µg/mL
Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake in a 
conc. dependent manner.
(Li et al., 2014)




Decreased B-A Papp. (Li et al., 2014)
PEG 400 




Increased A-B Papp. (Li et al., 2014)
100 µg/mL Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake. (Li et al., 2013)PEG 2000 










Decreased ER. (Li et al., 2014)
 0.1-100 
µg/mL
Scutellarin Sf9 MRP2 Uptake transport Increased the uptake in a 
conc. dependent manner.
(Li et al., 2014)
100 µg/mL Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake (Li et al., 2013)




Decreased ER. (Li et al., 2013)
0.1-100 
µg/mL 




Decreased ER. (Li et al., 2014)
Pluronic® F68 
10 µg/mL Baicalcein MDCKII MRP2 Bi-directional 
transport
Increased A-B Papp and 
decreased B-A Papp.
(Chen et al., 2017)




Decreased ER. (Li et al., 2013)
0.1-100 
µg/mL




Decreased ER in a conc. 
dependent manner. 
(Li et al., 2014)
0.1-100 
µg/mL
Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake in a 
conc. dependent manner.




10 µg/mL Baicalcein MDCKII MRP2 Bi-directional 
transport
Decreased B-A Papp. (Chen et al., 2017)
0.00005-
0.005% (w/w)
MDCKII MRP2 ATP 
measurements




Vincristine MDCKII MRP2 Uptake transport Increased intracellular accum. 
in a conc. dependent manner. 
Decreased IC50 value by 6.6 
times.




Doxorubicin MDCKII MRP2 Uptake transport Increased intracellular accum. 
in a conc. dependent manner. 
Decreased IC50 value by 125 
times.
(Batrakova et al., 
2003)




Decreased Vmax. (Batrakova et al., 
2004)




Decreased Vmax and increased 
Km.
(Batrakova et al., 
2004)
Pluronic® P85
10 µg/mL Baicalcein MDCKII MRP2 Bi-directional 
transport
Increased A-B Papp and 
decreased B-A Papp.
(Chen et al., 2017)
Pluronic® P85 +  
Pluronic® F68
10 µg/mL Baicalcein MDCKII MRP2 Bi-directional 
transport
Increased A-B Papp and 
decreased B-A Papp.
(Chen et al., 2017)
Pluronic® P85 +  
Pluronic® F127
10 µg/mL Baicalcein MDCKII MRP2 Bi-directional 
transport
Increased A-B Papp and 
decreased B-A Papp.
(Chen et al., 2017)






1520 Table 6: Nonionic surfactants inhibited solute carriers (SLCs) in vitro. 
1521
1522
1523 IC50 were estimated from upatke transport assay. For Regev et al. 2002, imact of surfactant on bi-
1524 directional transport assay was shown. 1-methyl-4-phenylpyridinium acetate (MPP+), Monocarboxylic 
1525 acid transporter (MCT, SLC16A1), Organic cation transporter 1 (OCT1, SLC22A1), (OCT2, 
1526 SLC22A2), (OCT3, SLC22A3), Peptide transporter 1 (PEPT1, SLC15A1), (PEPT2, SLC15A2), 
1527 Organic anion transporting polypeptide 1A2 (OATP1A2, SLC21A3), (OATP2B1, SLC21A9). Human 
1528 embryonic kidney cells stably transfected with OATP1A2 (HEK OATP1A2), or with OATP2B1 (HEK 
1529 OATP2B1), Chinese hamster ovary cells stably transfected with rbOCT1(CHO-K1 rbOCT1), Madin-
1530 Darby canine kidney cells stably transfected with OCT1-3 (MDCKII OCT1-3), or with PEP2 (MDCKII 
1531 PEPT2). Synonyms of surfactants available in Table 2 and 5.
1532
Pluronic® P105 transport decreased B-A Papp.
Pluronic® P105 10 µg/mL Baicalcein MDCKII MRP2 Bi-directional 
transport
Increased A-B Papp and 
decreased B-A Papp.
(Chen et al., 2017)
Polysorbate 80 0.05%  (v/v) Calcein-AM MDCKII MRP2 Bi-directional 
transport
Decreased B-A Papp. (Hanke et al., 2010)
TPGS 1000 0.01-0.05%  
(v/v)
Calcein-AM MDCKII MRP2 Bi-directional 
transport
Decreased B-A Papp. (Hanke et al., 2010)
100 µg/mL Scutellarin Membrane vesicles of 
Sf9 MRP2
Uptake transport Increased the uptake. (Li et al., 2013)




Decreased ER. (Li et al., 2013)
0.1 and 
1µg/mL









0.1 and 100 
µg/mL
Scutellarin Membrane vesicles of 
Sf9 MRP2 
Uptake transport Increased the uptake in a 
conc. dependent manner.





















Nonionic surfactant TransporterSLC Substrate Cells IC50 
Impact of surfactant 
Reference
OATP1A2 Estrone-3-sulfate HEK OATP1A2 0.0074% (Engel et al., 2012)
OATP1A2 Taurocholate HEK OATP1A2 0.0041% (Engel et al., 2012)
OATP2B1 Estrone-3-sulfate HEK OATP2B1 0.011% (Engel et al., 2012)
OATP2B1 Bromosulfophthalein HEK OATP2B1 0.00095% (Engel et al., 2012)
OCT1 MPP+ MDCKII OCT1 0.008% (Otter et al., 2017)
OCT2 MPP+ MDCKII OCT2 0.046% (Otter et al., 2017)
OCT3 MPP+ MDCKII OCT3 0.019% (Otter et al., 2017)
Solutol® HS 15 
PEPT2 Glycyl sarcosine MDCKII PEPT2 0.014% (Otter et al., 2017)
OATP1A2 Estrone-3-sulfate HEK OATP1A2 0.00054% (Engel et al., 2012)
OATP1A2 Taurocholate HEK OATP1A2 0.00034% (Engel et al., 2012)
Cremophor® EL
OATP2B1 Estrone-3-sulfate HEK OATP2B1 0.0011% (Engel et al., 2012)
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OATP2B1 Bromosulfophthalein HEK OATP2B1 0.0098% (Engel et al., 2012)
OCT1 MPP+ MDCKII OCT1 0.019% (Otter et al., 2017)
OCT2 MPP+ MDCKII OCT2 0.46% (Otter et al., 2017)
OCT3 MPP+ MDCKII OCT3 9.77% (Otter et al., 2017)
PEPT2 Glycyl sarcosine MDCKII-PEPT2 0.16% (Otter et al., 2017)
MCT Benzoic acid Caco-2 cells Decreased A-B Papp of 
the substrate in a 
concentration 
dependent manner.
(Rege et al., 2002) 
Kolliphor® P 188, 
Poloxamer 188
OCT3 MPP+ MDCKII OCT3 0.024% (Otter et al., 2017)
Kolliphor® P407 OCT1 MPP+ MDCKII OCT1 1.85 % (Otter et al., 2017)
OCT1 MPP+ MDCKII OCT1 0.002% (Otter et al., 2017)
OCT1 MPP+ CHO-K1 rbOCT1 85 ± 1.12 µg/ml (Soodvilai et al., 
2017)
OCT2 MPP+ MDCKII OCT2 0.033% (Otter et al., 2017)
OCT2 MPP+ CHO-K1 rbOCT2 295 ± 1.48 µg/ml (Soodvilai et al., 
2017)
OCT3 MPP+ MDCKII OCT3 0.011% (Otter et al., 2017)
Polysorbate 20
PEPT2 Glycyl sarcosine MDCKII-PEPT2 0.005% (Otter et al., 2017)






OCT2 MPP+ CHO-K1 rbOCT2 42 ± 1.15 µg/ml (Soodvilai et al., 
2017)
OCT1 MPP+ MDCKII OCT1 0.0007% (Otter et al., 2017)
OCT1 MPP+ CHO-K1 rbOCT1 106 ± 1.20 µg/ml (Soodvilai et al., 
2017)
OCT2 MPP+ MDCKII OCT2 0.039% (Otter et al., 2017)
OCT2 MPP+ CHO-K1 rbOCT2 185 ± 1.20 µg/ml (Soodvilai et al., 
2017)
OCT3 MPP+ MDCKII OCT3 0.011% (Otter et al., 2017)
PEPT2 Glycyl sarcosine MDCKII PEPT2 0.037% (Otter et al., 2017)
Polysorbate 80
PEPT1 Glycyl sarcosine Caco-2 cells Decreased A-B Papp of 
the substrate in a 
concentration 
dependent manner.
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